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Renal Cell Carcinoma (RCC) is the most common and fatal type of kidney cancer. Over 30% of 
patients that are diagnosed with RCC exhibit metastases. Almost 88% of patients with distant 
metastases succumb to the disease within 5 years of diagnosis. Kidney Injury Molecule-1 (KIM-
1) is a cell surface glycoprotein that is not expressed in a healthy kidney but becomes highly 
expressed on proximal tubular epithelial cells (PTECs) following injury. Data from the Cancer 
Genome Atlas (TCGA) reveals that >90% of RCC tumours express KIM-1 mRNA and that 
higher expression levels correlate with increased overall survival rates of patients. The 
pathophysiological role of KIM-1 in RCC is not well understood. Using human (786-O) and 
murine (RENCA) models, we recently uncovered that KIM-1 may inhibit the metastatic 
properties (invasion and extravasation) of RCC cells using in vivo and in vitro systems. The aim 
of this thesis work was to elucidate the mechanism by which KIM-1 regulates RCC tumour 
progression using syngeneic and pre-clinical orthotopic RENCA models. 
 
Transcriptomic analysis of RENCA cells lacking or overexpressing KIM-1, and The Cancer 
Genome Atlas (TCGA), revealed significant upregulation of genes involved in extracellular 
matrix (ECM) interactions in association with KIM-1 expression.  In vivo, subcutaneous 
implantation of RENCA tumours resulted in the development of thick, collagen dense, stromal 
capsules surrounding the tumours. This was observed in both immune-competent and immune-
deficient mice. In a pre-clinical (orthotopic) model, KIM-1 expression inhibits primary RENCA 
tumour growth within the kidneys. Lastly, significant phenotypic differences in primary tumour 
growth, and histology were observed in between subcutaneous and orthotopic implantation of 
RENCA tumours.  
Lay Summary 
Kidney cancer comprises almost 4% of all adult malignancies and is the 8th most common type 
of cancer in humans. Renal Cell Carcinoma (RCC) is the most common and lethal type of kidney 
cancers. RCC is most lethal when it spreads to distant sites because it is resistant to many forms 
of anti-cancer therapy including chemo-, radio- and even modern immunotherapies. Over one 
third of patients have cancer that has spread at the time of diagnosis. Kidney Injury Molecule-1 
(KIM-1) is a normal protein that is found in injured human kidneys and is aberrantly present in 
over 90% of RCC tumour samples obtained from cancer patients. Patients whose tumours have 
high amounts of KIM-1 seem to survive longer (due to cancer spread likely) but the reason for 
this is not known.  The objective of my thesis was to determine how KIM-1 may protect patents 
with RCC from dying using genetic techniques and animal models of kidney cancer.   
 
My work suggests that the role of KIM-1 in RCC greatly depends on the tumour model used. 
Overall, KIM-1 may protect patients with RCC by slowing the growth of tumours, and 
potentially, the spread of cancer cells to distant sites from the primary tumour. Our genetic 
studies suggest that KIM-1 may achieve this by altering the genes produced by the kidney 
tumours to produce a thick, collagen dense “capsule” around them.  Further studies of these 
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Cancer is defined as a group of diseases that is caused by abnormal cells undergoing 
uncontrolled proliferation within any part of the human body that has the potential to invade 
nearby tissues or spread to distant tissues. Tumours consist of a (solid) collection of cells which 
can be benign or malignant.  Malignant tumours are made up of cancerous cells which can cause 
death by infiltrating or destroying normal (local or distant) tissues (World Health Organization, 
2018). Globally, cancer is the second leading cause of death – 1 in 6 deaths are caused by cancer 
(World Health Organization, 2018). According to the American Cancer Society in 2020, 
1,806,590 new cancer cases were reported, with a total of 606,520 deaths (Siegel, Miller and 
Jemal, 2020). The Canadian Cancer Society, in 2019, estimated that nearly 1 in 2 Canadians will 
be diagnosed with cancer within their lifetime. In 2019 alone, it was estimated that 220, 400 new 
cases of cancer were expected to be diagnosed in Canada. Out of these expected cases, males 
have a slightly higher incident rate than females, with numbers at 113,000 cases vs 107,400 cases 
respectively. The risk of developing cancer in Canada has increased significantly with our aging 
population (Canadian Cancer Statistics Advisory Committee, 2019). Genetic alterations to 
cellular DNA and/or environmental effects are believed to be central to the development of many 
types of cancer. Unhealthy diets, physical inactivity, drug and alcohol abuse are all 
environmental factors that have been linked to an increased incidence of cancer worldwide. 
Various chronic infections can increase the risks of cancer development. For example, chronic 







development of pyloric and cervical cancer, respectively. One of the most common causes of 
death from cancer is the process of metastasis (World Health Organization, 2018). Metastasis is 
the process by which cells within a primary tumour break away from their originating boundary 
of growth, travel and inhabit local (neighboring) or distant tissues, resulting in the growth of a 
secondary tumour.  
Hanahan and Weinberg famously proposed the six characteristics needed for cancer progression. 
These have been coined the hallmarks of cancer (Hanahan and Coussens, 2012). The six 
fundamental hallmarks of cancer include: sustained cell proliferation signaling, evading tumour 
and/or growth suppressors (e.g., immune system), invasion and metastasis, immortal replication, 
induction of angiogenesis and lastly resisting cell death.  All of the listed hallmarks are key 
characteristics present in the vast majority of human cancers. These hallmark properties allow 
cancers to promote site specific inflammation, genetic instability leading to additional mutations, 
and evasion of immune destruction. These processes also allow for the cancerous cells to recruit 
non-neoplastic cells to the site of malignancy (e.g., macrophages), in order to benefit the cancer's 
progression. Critically investigating these mechanisms for specific cancers, allows us to have a 










Figure 1. Hallmarks of Cancer  
The six original hallmarks of cancer (Hanahan and Weinberg) along with newly found 
mechanisms that contribute to progression and metastasis (adapted with permission from 
Hanahan and Weinberg, 2011). Diagram including potential cancer therapeutics that can help 
combat the above mechanisms to benefit cancer treatment.  
 
1.2 Renal Cell Carcinoma  
Kidney cancer has been identified as the 8th most common form of cancer, causing 179,386 
deaths globally in 2020 alone (Globocan, 2020). Renal cell carcinoma (RCC) is the most 
common form of kidney cancer, compromising up to 85%-90% of all cases (Chang et al., 2016). 







Statistics 2019 found from the approximate 100,000 new cases of cancer, renal and pelvic 
cancers have affected 4.2% and 2.3% of males and females, respectively (Canadian Cancer 
Statistics Advisory Committee, 2019). RCC is characterized as being a highly immunogenic 
cancer – where RCC tumours are recognized  as foreign and elicit a strong adaptive immune 
response against it. By definition, the occurrence of RCC implies that these tumours evade the 
host’s immune system. The survival rates vary greatly depending on the progression and 
presence of metastasis. If RCC is detected early while still being localized to the affected kidney 
(contained within the Gerota’s fascia), surgical resection can be curative, although recurrence 
occurs in 20%-40% of those who have undergone surgical management (Chin et al., 2006).  
Patients with distant metastases (metastatic RCC) have significantly reduced survival rates 
(American Cancer Society, 2016). Specifically, approximately 12% of patients with advanced 
disease die within 5 years of initial diagnoses (Choueiri and Motzer, 2017). 
1.2.1 RCC Subtypes and Histological Properties 
Histological analysis of RCC tumours is extremely important in determining patient prognosis as 
it aids not only in the diagnosis but also provides information about the histopathological type of 
RCC. Nephrectomy is used to make a tissue diagnosis before embarking on treatment. On rare 
occasions, percutaneous biopsy of small renal masses is undertaken if there is a high degree of 
suspicion of a metastatic lesion to the kidney from another type of cancer (Sahni and Silverman, 
2009).  
RCC is classified using histology into subtypes; Clear Cell Carcinoma (ccRCC) compromising 
~75%, Papillary RCC (pRCC) compromising ~10%, Chromophobe RCC compromising ~5%, 







Kaelin, 2011). Up to 5% of RCC remain unclassified. The cellular morphology of ccRCC is 
characterized by cells with a lipid-rich cytoplasm. For pRCC, subtype 1 consists of spindle-
shaped cells surrounding a basal membrane, and subtype 2 consists of spindle-shaped cells with 
visually prominent nuclei and an eosinophilic granular cytoplasmic space. Collecting Duct RCC 
histologically will present abnormal cells infiltrating the walls of the collecting ducts, causing a 
significant desmoplastic reaction. Lastly, Medullary RCC represents neoplasms localized to the 
distal nephron, characterized by hyperchromatic nuclei (Muglia and Prando, 2015). 
1.2.2 Staging  
Staging studies are crucial to developing a therapeutic plan for affected patients.  A variety of 
imaging modalities are used to determine the size of the tumour as well as the extent of local and 
regional involvement. The most widely used is the (The American Joint Committee on Cancer 
(AJCC), 2017) Tumour, Node, Metastasis (TNM) (anatomic) staging system and it is used for 
staging all histological variants of RCC.  The anatomic extent of disease is the most consistent 
predictor of prognosis in patients with RCC. In early stages – classified as either stage I or II - 
tumours can be any size (<7cm stage I, >7cm stage II) in diameter but are localized to the 
affected kidney only. Stage III is characterized by tumours of an undefined size within the 
affected kidney and metastasis to regional lymph nodes and/or into the major veins or 
perinephric tissues (but not beyond the Gerota’s fascia of the kidney or into the ipsilateral 
adrenal gland) (Reznek, 2004). Lastly, stage IV is characterized by tumours that have spread 
beyond the Gerota’s fascia to nearby tissues including the ipsilateral adrenal gland (Sandock, 
Seftel and Resnick, 1997). When metastatic disease is suspected at initial presentation, 
pathologic confirmation is obtained prior to starting therapy. The most common sites of 







(Shao et al., 2019). Although approximately 65% of tumours are limited to the kidney (Stage I-
III) at initial diagnosis, over 20% of these patients will experience a relapse after receiving 
definitive treatment (Shao et al., 2019).   
1.2.3 Risk Factors and Causes  
A number of established risk factors exist for the development of RCC and include both genetic 
and environmental factors. A number of hereditary kidney cancer syndromes have been 
described including autosomal dominant polycystic kidney disease, Tuberous Sclerosis Complex 
and Von Hippel-Lindau disease (Gnarra et al., 1994; Keith et al., 1994; Yang et al., 2014). The 
most common genetic alteration found in patients with sporadic RCC is the mutation of the von 
Hippel-Lindau tumour suppressor gene, also known as the VHL gene. Similar to many genes, 
VHL is co-dominantly expressed. In familial RCC, gene alterations of one inherited allele causes 
patients to exhibit VHL disease predisposing them for RCC tumour growth. In sporadic RCC, 
both alleles of the VHL gene are functional at birth, yet bi-allelic gene alterations occur 
postnatally causing the spontaneous development of RCC (Ma et al., 2001).  
The VHL gene is located on chromosome 3p region and encodes for the VHL protein. VHL 
protein acts as a tumour suppressor gene by regulating cellular division and preventing increased 
proliferation (Gnarra et al., 1994). The VHL protein is mostly commonly known to form a stable 
protein complex with elongin C and B, as well as proteins Cul-2 and RBX-1 (Pause et al., 1997). 
This VHL protein complex functions as a ubiquitin-protein ligase, that has many downstream 
effector targets. In normoxic, healthy conditions - where the VHL gene is unaltered – the VHL 
protein complex is able bind to the hydroxylated form of hypoxia inducible factor 1-alpha (HIF-







ubiquitination. Under conditions of hypoxia, HIF-2α escapes ubiquitination by VHL as it is not 
hydroxylated by oxygen-dependent prolyl hydroxylases (Groulx and Lee, 2002). Under 
conditions where the VHL gene is altered and non-functional, the VHL protein complex is 
unable to bind to hydroxylated HIF-1α and thus unable to target the complex for destruction. 
Due to this, HIF-1α becomes continuously expressed on cells leading to the enhancement of 
downstream HIF transcription factors, also acting as a positive feedback loop. Overall, increased 
HIF transcripts result in cellular dysregulation. For example, HIF-2α enhancement mimics 
hypoxic cellular conditions activating apoptotic and glycolytic pathways, while increased HIF-2α 
enhances angiogenesis and cell proliferation. Inactivation of VHL results in upregulation of 
VEGF, which results in increased metabolism and angiogenesis (Verine et al., 2010). Overall, 
the HIF-2α transcripts together with the malignant tumour microenvironment (TME) resulting 
from excess VEGF drive the development and progression of RCC (Rechsteiner et al., 2011).   
1.2.4 Treatments for RCC    
1.2.4.1 Surgery 
As of today, there is no therapy for RCC that is guaranteed to be curative, but some patients have 
experienced complete and permanent remission. The field has seen many advancements in 
therapeutics owing to recent breakthroughs in cancer immunology. Treatments options for RCC 
range from surgical resection to non-targeted (older) drugs, to molecular targeted therapies, to 
novel immunotherapies and various combinations of these which are currently being tested in 
clinical trials. The most successful and tried form of treatment for localized RCC (stage I-III) is 
surgical resection, either through partial or radical nephrectomy. This consists of the removal of 
only a portion of the kidney containing the tumour, removal of one affected kidney, or removal 







Cancer Institute, 2020). Unfortunately, surgery has major limitations as a primary treatment. 
Nephrectomy is indicated for patients with tumours contained within the kidney’s Gerota’s fascia 
(stages I-III) (Reznek, 2004). Radical or partial nephrectomy have been found to improve 
patients' 5-year survival rate. However, in patients that present with metastatic RCC, surgery 
alone is not a feasible form of treatment, and is only used in order to reduce painful symptoms or 
as cytoreductive treatment in combination with systemic therapy (De Vivar Chevez, Finke and 
Bukowski, 2014).  
1.2.4.2 Targeted Therapies 
Decades of research into the pathogenesis of clear cell RCC (the most common subtype), 
including the discovery of the roles of HIF-2 and VEGF, have led to the development of a 
myriad of molecular targeted therapies for patients with RCC (Cho et al., 2016; Choueiri and 
Kaelin, 2020). Instead of enhancing mechanics of the immune system to combat disease, 
molecular targeted therapies attack or inhibit mechanisms that assist directly in cancers 
progression (see hallmarks of cancer above). These include inhibiting processes such as 
angiogenesis and increased proliferation. The knowledge of the crucial role of mammalian target 
of rapamycin (mTOR) and vascular endothelial growth factor (VEGF) (or its receptor) in the 
progression and metastases of RCC have greatly improved treatments of metastatic RCC (Heng, 
Kollmannsberger and Chi, 2010). mTOR is a highly conserved protein kinase that regulates cell 
proliferation, apoptosis, along with various signaling biological pathways within the body. 
mTOR is a downstream effector of the PI3-K/Akt/mTOR pathway. This signaling pathway is 
activated in RCC tumours, playing a significant role in cell proliferation, tumour metabolism, 
and immune cell differentiation also creating a positive feedback loop. Initiating the PI3-







activation of tyrosine kinase receptors (Porta, Paglino and Mosca, 2014). This interaction 
mediates intracellular PI3-K to phosphorylate PIP2 into PIP3. PIP3 then binds to the activated 
PDK1/2 complex which downstream binds to Akt at its PH domain, allowing activation through 
phosphorylation (Battelli and Cho, 2011). When Akt is in its activated state, it has the ability to 
inhibit the tumour suppressor complex TSC1/TCS2. Downstream, this complex inhibits Rheb 
GTPase – a crucial player in the inhibition of mTOR signaling pathway in cancer. With 
inhibition of the tumour suppressor TSC1/TCS2 complex and Rheb, mTOR signaling allows for 
anabolic proliferation and dysregulation of cellular functions (Huang and Manning, 2008). 
Allosteric inhibitors of mTOR such as temisirolimus and everolimus, have shown significant 
anti-tumour effects in patients with advanced staged RCC. Combination strategies also increase 
efficacy and overall patient response.  
Another targeted therapy commonly used in RCC treatment is anti-VEGF. VEGF is identified as 
an important mediator in the development and progression of RCC, as it greatly impacts tumour 
vascularity and thus metabolism (Stitzlein, Rao and Dudley, 2019).  Specifically, HIF 
transcription factors target genes such as VEGF, PDGF, IGF, and TGF- which directly 
implicate alterations in angiogenesis, glucose transport, apoptosis, cell signaling, and pH 
regulation. Various multi-kinase inhibitors such as sorafenib, are able to inhibit VEGF, PDGF, c-
Kit receptor tyrosine kinases and show positive results in reduction of disease in metastatic RCC 
patients, with feasible toxicity (Larkin and Eisen, 2006).  
1.2.4.3 Immunotherapies  
Other forms of treatment involve the use of immunotherapies. Immunotherapy is a form of 







cancer. Immunotherapies are an integrated form of therapy for RCC yet have shown positive 
results due to RCCs immunogenic nature. In the early 1990’s, Interleukin-2 (IL-2) and IFNγ 
were the first cytokine specific treatments used to treat metastatic RCC. These two cytokines 
were chosen because: IL-2 promotes T-cell activation and effector function; and IFNγ triggers 
activation of T-cells, enhances antigen presentation by antigen-presenting cells and promotes 
activation of macrophages (Tau and Rotherman, 2001). In 1992 the FDA approved high-dose IL-
2 as a treatment for advanced RCC (Rosenberg, 2007). Patients experienced overall response 
rates of up to 25%, although IL-2 was not well-tolerated amongst patients due to its toxicity at 
high doses.  Later on, IFNγ was tested as a monotherapy for metastatic RCC patients. Clinical 
trials began using low-to-moderate doses of IFNγ – as they were deemed more biologically 
effective in previous in vivo experiments rather than higher doses. Early-stage clinical trials 
consisted of doses at 100g/patient administered once per week, resulting in promising outcomes 
where the total response rate was 30%, and well tolerated by patients (Aulitzky et al., 1989). In 
trials with patients with later stage disease, there was found to be no significant difference 
between both response and survival rates when comparing placebo to treatment. Hence, IFNγ as 
a monotherapy was not further investigated for RCC treatment. With these promising results, 
combination therapy of IL-2 and IFNγ began to be administered to RCC patients. Although these 
results were positive, only a small fraction of patients responded to the therapy, albeit 
incompletely (Escudier et al., 1993). 
More recently, the field has seen the emergence of ground-breaking immunotherapies that target 
T cell checkpoints (e.g. programmed cell death ligand-1 (PDL-1) and programmed cell death-1 
(PD-1) and/or CD80/CD86 and cytotoxic lymphocyte antigen 4 (CTLA-4)). The agents are 







PD-1 is a receptor expressed on antigen presenting cells of the immune system, and when bound 
by its ligand PDL-1 – commonly found on antigen presenting cells and some cancer cells 
(Weinstock and McDermott, 2015) – suppresses T cell activation, allowing the tumour to escape 
immune destruction primarily through the exhaustion of cytotoxic CD8+ T cells (Lu et al., 2019). 
These immunotherapies have shown favorable results in in clinical trials when delivered as a 
monotherapy or in combination with other immunotherapies (anti-CTL-4) (Motzer et al., 2018). 
Therapy was associated with an increase in intratumoural T-cell tracking, reduced 
immunosuppressive cytokines and T-regulatory cells, as well as an increase in anti-angiogenic 
properties (Weinstock and McDermott, 2015). In the process of T cell activation/priming, two 
positive activating signals must take place between T cell and antigen presenting cells (APCs) to 
allow for the success of T-cell priming. Stimulatory signal consists of the T-Cell Receptor (TCR) 
to the Major Histocompatibility Complex (MHC) presenting the unknown peptide, along with 
CD28 engagement on T-cells to CD80/CD86 on the APC. During times of autoreactivity 
(Boehncke and Brembilla, 2019), CTLA-4 on T-cells will bind to CD80/CD86 on the surface of 
APCs sending a inhibitory signal, rendering the T cell to become inactive (Buchbinder and 
Desai, 2016). CTLA-4 - an inhibitory molecule binds to CD80/CD86 (B7-1/B7-2) with much 
greater affinity than CD28 on T cells, and when engaged delivers an inhibitory signal to 
activated T cells (Pardoll, 2012). In cancer, blocking the inhibitory signal between CTLA-4 and 
CD80/CD86 has been found to enhance both priming and activation of T cells and various 
immune cells (Tang et al., 2018). Thus, using monoclonal agonist antibody anti-CTLA-4 
(Ipilimumab) as an immunotherapy in RCC, has been shown to increase T cell effector functions 
resulting in enhanced anti-tumour immunity (Seidel, Otsuka and Kabashima, 2018). 







synergistic effects on anti-tumour immunity, being able to increase overall response rates against 
malignancies (Motzer et al., 2018). Although this therapy has been shown to cause progression-
free outcomes with increased overall survival, there is still a major limitation of patient-patient 
variation in response (Cairns, 2011). Also, the overall response rates have been low (Weinstock 
and McDermott, 2015). 
1.2.5 Patient Immune Profile or Immune Microenvironment 
To enhance potential treatments, patient profiles have been examined to comprehend the 
immunological mechanisms throughout the clinical stages of RCC. Many clinical studies have 
evaluated patient serum for cytokine levels, indicative of the immune phenotype and tumour 
microenvironment present. A recent clinical study aimed to find differences in tumour-associated 
interleukins (IL) and cytokines from collected metastatic RCC patients treated with IL-2 
immunotherapy and compare the results of serum from healthy donors. This study aimed to find 
differences in immunomodulatory cytokines such as IL-10, IL-6, IL-12, IL-8, and IL1β, as well 
as tumour necrosis factor-alpha (TNFα). Results found higher levels of cytokines that implement 
an immunosuppressive effect; increased IL-8, IL-6, and c-reactive protein. Patients found to have 
an immunosuppressive cytokine profile correlated directly with an overall reduced survival rate 
(Guida et al., 2007).  
1.2.6 The Tumour Microenvironment (TME) 
The tumour microenvironment (TME) is made up of cancer cells, stromal tissue, and 
surrounding extracellular matrix. The immune system plays a fundamental role in shaping the 
TME. Intense study of the complex interactions between cancer cells and the host immune 







creates an environment that promotes tumour progression throughout all stages of malignancy. In 
immunogenic cancers, similar to RCC, the TME contains a vast variety of immune cells such as 
CD8+ T cells, γδ T cells, along with fibroblasts, and endothelial cells (Hanahan and Coussens, 
2012). The types of immune cells (e.g. T cells, innate lymphoid cells, macrophages etc.) within 
the TME are believed to be dependent on cell-cell communications between the RCC cells, the 
extracellular matrix and immune cells. Various studies investigating the transcriptomic profile of 
human RCC tumours have allowed for a clearer understanding of the components within RCC 
TME. This information has helped us to understand why RCC is able to evade immune 
destruction, despite being a highly immunogenic cancer. Immune signatures that are commonly 
observed in RCC are the expression of tumour promoting checkpoint inhibitors PD1, PDL1, and 
CTLA-4. Histopathologic and transcriptomic analysis  of RCC tumours has identified three 
distinct immune profiles : 1) T cell enriched tumours that are infiltrated with an abundant 
quantity of T-Lymphocytes; 2) Non-infiltrated tumours that have a scarcity of infiltrating 
immune cells, and 3) Heterogenous tumours that are composed of diverse amounts of immune 
cells alongside the malignant cells. RCC tumours follow the phenotype of 1) or 3) – being a 
cancer with one of the highest T cell infiltrates and/or having tumours with heterogenous 
immune profile containing diverse types immune cells. Despite this immunogenic feature of 
RCC tumours – many patients succumb to the disease. A majority of RCC patients present with a 
heterogenous immune profile – although seemingly beneficial to patients - outcomes of this 
TME result in the poorest survival. The abundance of antigen presenting machinery also does not 
have clear correlations with tumour progression.  Thus, analyzing specific immune cell effector 
functions along with their abundance can better help understand why these highly infiltrated 







contain vast levels of mainly CD8+ T cells, neutrophils, macrophages, and plasmacytoid 
Dendritic Cells (pDC). Higher frequencies of cytotoxic cells such as CD8+ T cells within the 
TME is a characteristic that would seem to be extremely beneficial to patients, yet with RCC, 
high correlations of CD8+ T cells alone do not correlate to increased survival. Instead, a higher 
ratio between cytotoxic and immune regulatory cells improve survival; specifically, the balance 
between CD8+ T cells and T regulatory cells (Tregs) is shifted to CD8+ T cells. Tregs are a 
specialized immune cell able to suppress T cell proliferation and activity; known to inhibit 
autoimmunity, yet in cancer are able to suppress anti-tumour T cell immunity (Romano et al., 
2019). Heterogenous RCC tumours have significant changes when compared to T cell enriched 
profiles, suggesting that the T cell enriched tumours have distinct gene alterations that cause this 
unique immune profile (Şenbabaoğlu et al., 2016). The enhancement of the T cell enrichment in 
RCC tumours could be due to genomic alterations that generate neoantigens or make existing 
antigens more immunogenic (Germano et al., 2017) .  
Another common phenotype observed in the TME of multiple cancer types is the abundance of 
extracellular matrix (ECM). ECM is a crucial component of the TME – able to influence tumour 
cell activity and biosynthesis (Xu et al., 2019). A major component of the ECM are the collagens 
present (Nissen, Karsdal and Willumsen, 2019). Several mutated genes influence the interaction 
between cancer cells and the elements compromising the ECM, which can contribute to 
increased production of collagen (Xu et al., 2019). Collagen activity such as degradation and re-
deposition within a tumour can affect several processes in cancer progression such as infiltration, 
invasion, migration, and angiogenesis. The role of collagen in cancer has been found to have a 
paradoxical effect by both promoting and inhibiting tumour progression throughout cancer 







inhibit lymphocyte locomotion in both human melanoma and RCC (Applegate, Balch and Pellis, 
1990). In human lung tumours, collagen deposition is directly related to decreased intratumoural 
cytotoxic CD8+ T cells – specifically, collagen is found to induce CD8+ T cell exhaustion 
through collagen receptor interaction of LAIR1. More importantly, this study also revealed that 
increased collagen deposition is able to promote immune checkpoint blockade PD-1/PDL-1 
resistance (Peng et al., 2020). On the other hand, hypermethylation thus inactivation of specific 
collagen genes such as collagen type 1  2 (COL1A2), increase invasive capabilities of human 
bladder cancer (Mori et al., 2009). Specifically, the role of collagen on RCC tumour progression 
is not fully understood. Using both TCGA database and histological analysis of ccRCC human 
tumours have revealed that collagen type 23   (COL) correlates with larger tumour sizes 
and decreased overall survival, respectively (Xu et al., 2017). Tumour tissue bank analysis has 
also implicated collagen type 6   (COL6A1) to be a predictive marker for overall survival of 
ccRCC patients (Wan et al., 2015). Although RCC immune profiles and TME associated genes 
of interest (COL23A1 and COL6A1) have been classified, the mechanisms that occur to 
differentiate these microenvironments are not well understood. In order to combat this disease, 
we must elucidate the cellular mechanisms that cultivate a malignant TME in RCC tumours.  
1.2.7 Murine Models for Renal Cell Carcinoma  
 
A variety of murine models are used to study the in vivo progression and metastasis of RCC. 
Murine models of RCC have been found to accurately reflect human disease and can be used 
widely in experiments investigating primary and secondary tumour progression, as well as 







that are widely used in the in vivo research of RCC are syngeneic models, xenograft models, and 
genetically engineering mouse models (GEM).  
1.2.7.1 Syngeneic & Genetically Engineered Mouse (GEM) Models of RCC 
 
The two major types of cancer models are the spontaneous and transplanted tumour models. 
Recent breakthrough in our understanding of genetic defects in clear cell RCC has led to the 
development of new spontaneous models of murine RCC (Harlander et al., 2017).  However, the 
vast majority of RCC research has relied on transplant models in mice (Sobczuk et al., 2020).  
Syngeneic models are the transplantation of a cancer cell line that has the same genetic 
background as the host (mouse). One of the most widely used murine syngeneic models of RCC 
is the Renca model where the murine RCC cell line is transplanted into BALB/c Wild-type mice. 
This mouse model is syngeneic because Renca is a murine RCC cell line that was derived from a 
BALB/c mouse that spontaneously developed a renal malignancy (Murphy and Hrushesky, 
1973). There are many advantages to using the syngeneic mouse model – they are more 
economical and simplistic. Syngeneic models have been crucial to developing and studying the 
mechanism of novel immunotherapeutics for RCC, including immune check-point inhibitors. For 
instance, this model allows for the investigation of how the immune system interacts with the 
cancer – this has permitted investigations of tumour immune profiling as well as tumour 
microenvironmental changes that occur in RCC. Another commonly used murine model is 
genetically engineered mouse (GEM) models. The GEM models are created by introducing 
genetic alterations of possible genes of interest thought to be involved in the progression of 
disease. This can include one or more genes that can be deleted, mutated, or overexpressed 









Another tumour transplant mouse model that is commonly used is the xenograft model. Here 
human derived cell lines or tissues are implanted into either humanized or immune deficient 
mice. These models can be differentiated in two forms of experimental use: xenografts using 
conventional cell lines, or xenografts using patient derived specimens. Commonly used mice for 
xenograft implantation are Rag1-/- deficient mice, severely compromised immunodeficient 
(SCID) mice, or nude mice (lack thymi and hence T cells). Each murine model has an 
insufficient adaptive immune response, allowing for neo-antigens of the human derived 
transplanted cell lines to pass immune surveillance and create a tumour (Richmond and Yingjun, 
2008). Xenografts are more clinically relevant because they utilize human cells, yet are limiting 
due to genetics and histology poorly reflecting human cancers (Becher and Holland, 2006).  
 
1.2.7.3 Limitations of Murine Models 
 
Each tumour model has its advantages and disadvantages, but as a whole, they have aided 
scientists to better understand the biology of RCC. Some are more clinically relevant and better 
suited for testing potential therapies. Unfortunately, a vast majority of kidney cancer cell lines 
are not compatible with syngeneic and GEM murine models. Many syngeneic models are used 
within rodents such as mice and rats, yet poorly reflect the development and progression of 
human cancers.  The mouse models that correlate best with clinical findings in patients are the 
xenograft and GEM models as they mimic the genetic alterations and/or histological properties 
of human RCC (Sobczuk et al., 2020). Although, GEM models often poorly predict human 
tumour response to therapy (Richmond and Yingjun, 2008). Another major pitfall of the 







model is made of mouse cells. Due to this, tumour microenvironmental studies may not 
accurately represent that of the human RCC TME. 
1.2.7.4 Subcutaneous vs. Orthotopic (pre-clinical) Models of RCC 
 
Syngeneic, xenograft, and GEM models can all undergo cancer cell line injections using 
different methods of implantation. Subcutaneous delivery is the most common form of cancer 
cell line implantation – it is the process of injecting cancer cells in the space underneath the skin 
and above the muscle, commonly within the flanks of mice. Although this model allows for the 
easy establishment and monitoring of tumours over the skin using calipers, this mode of 
implantation does not reflect the natural microenvironment of human RCC. A more clinically 
relevant model of RCC is the orthotopic model – here RCC cell lines are implanted into the 
kidney (where RCC originates in the human body). Orthotopic injections can be performed with 
syngeneic, xenograft, and GEM mouse models (Richmond and Yingjun, 2008). Orthotopic 
implantations have been shown to mimic primary tumour progression, local invasion and 
spontaneous metastases to distant organs such as the lymph nodes, lungs and liver as observed in 
human RCC (Salup, Herberman and Wiltrout, 1985).  
1.3 Kidney Injury Molecule-1 
 
Kidney injury molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor 1 
(HAVCR1) or T cell immunoglobulin receptor mucin domain 1 (TIM-1) , is a cell-surface 
receptor (Han et al., 2002). KIM-1 belongs to the TIM family of glycoproteins which are type-1 
transmembrane proteins consisting of an extracellular immunoglobulin like IgV domain, a hyper-
glycosylated mucin domain, a transmembrane domain and an intracellular cytoplasmic domain. 







spleen, T cells and B cells– possessing multiple functions including its involvement in acute 
kidney injury and repair, hepatitis A virus infection, T cell trafficking and autoimmunity 
(Bonventre, 2009; Zheng et al., 2019). In the kidney, KIM-1 is not expressed during a healthy 
state but is the most upregulated protein following acute kidney injury (Ichimura et al., 1998). 
KIM-1 is specifically expressed on the apical surface of proximal tubule epithelial cells (PTECs) 
immediately following kidney injury (Bonventre, 2008; Ajay et al., 2014). Interestingly, KIM-1 
undergoes spontaneous and accelerated (with more injury) ectodomain shedding releasing the 
cleaved or soluble KIM-1 into the lumen of the kidney, ultimately ending up in the blood and 
urine of affected patients (Gandhi et al., 2014). This makes KIM-1 a sufficient clinical biomarker 
for kidney injury in the urine and plasma of humans, mice, and rats (Sabbisetti et al., 2014). 
1.3.1 Function of KIM-1 in the Kidney 
 
The IgV portion of KIM-1 contains an ion-dependent ligand binding domain that forms an active 
site for recognition of the membrane phospholipid, phosphatidylserine (PtdSer) (Santiago et al., 
2007) – “eat me” signal - that is expressed on the outer surface of early necrotic and apoptotic 
cells. KIM-1 is a scavenger receptor that is able to recognize other “eat me” signals on apoptotic 
cells such as oxidized low-density lipoproteins (LDL) (Ichimura et al., 2008). Thereby, KIM-1 
enables PTECs to engulf apoptotic cells, promoting repair and regeneration of the renal tubules 
following acute kidney injury (Yang et al., 2015; O. Z. Ismail et al., 2016). Binding of KIM-1 to 
apoptotic cells triggers intracellular signaling via its cytosolic domain to inhibit NF-kB activation 
and downregulate  Toll-like receptor 4 expression (Yang et al., 2015). The clearance of necrotic 
cells, which predominate after acute kidney injury, is also facilitated by KIM-1 expressing 
PTECs, but this requires the opsonin, Apoptosis Inhibitor of Macrophages (AIM), which is 







necrotic debris and cells, subsequently allowing KIM-1 to bind to AIM and engulf the debris via 
KIM-1/PTEC mediated phagocytosis (Arai et al., 2016).  This rapid clearance of dead cells 
prevents excess inflammation build up and the release of danger associated molecular patterns 
(DAMPs) from the apoptotic cells (Kobayashi et al., 2007). 
1.3.2 KIM-1 in RCC 
 
KIM-1 expression is elevated in approximately 80%-90% of human RCC patients, specifically 
expressed in both clear cell RCC and papillary RCC – two of the most common forms of RCC 
(Han et al., 2005; Lin et al., 2007). Both of these subtypes of RCC have allowed for the non-
invasive surveillance and early detection of RCC development through detectable levels of 
soluble/shed KIM-1 in patients plasma and urine (Han et al., 2002). Urinary KIM-1 is 
significantly upregulated in RCC patients prior to surgical nephrectomy, and subsequently 
reduced either with notable reduction or complete absence of urine KIM-1 post-nephrectomy 
(Zhang et al., 2014). Recent studies have also shown that as early as 5 years before initial 
diagnosis of RCC, KIM-1 is upregulated in the plasma of patients (Scelo et al., 2018). 
The pathophysiological role of KIM-1 in human RCC is not well known. There have been 
several studies that have proposed conflicting roles for KIM-1 in RCC.  Research by Scelo and 
Muller et al., 2018 found that increased plasma concentrations of KIM-1 were associated with 
worse survival rates in RCC patients (Scelo et al., 2018). Another study by Cuadros et al., 2014, 
studied intrinsic mechanisms involved in the progression of RCC. Specifically, this study 
analyzed the human RCC cell line, 769-P where KIM-1 is basally overexpressed, by silencing its 
expression and reported  that KIM-1 directly activates IL-6/STAT-3/HIF-1 axis, in turn 







activation of IL-6/STAT-3/HIF-1, is dependent on KIM-1 ectodomain shedding (Cuadros et al., 
2014).  
 
1.4 Rationale, Objective and Hypothesis  
1.4.1 Rationale  
 
Renal cell carcinoma (RCC) is the most common and lethal type of kidney cancer (Cohen and 
McGovern, 2005). RCC originates within the proximal convoluted tubules of the kidney, and can 
metastasize to the adrenal gland, nearby lymph nodes, and distant organs such as the lungs. 
Despite the fact that RCC is characterized as a highly immunogenic cancer, >30% of patients 
present with (local or distant) metastatic disease at initial diagnosis, with >88% of these patients 
dying within 5 years (Decastro and McKiernan, 2008; Choueiri and Motzer, 2017). As of today, 
there is no cure for RCC, and the current treatments are inadequate.  
The primary form of treatment for localized RCC is surgical resection of the tumour. Although 
this treatment is very common, the method is problematic for metastatic RCC. Current 
treatments for metastatic RCC include immunotherapies (Motzer et al., 2019) and targeted 
therapies (e.g. sunitinib) that focus on immune checkpoints (Motzer et al., 2013). There is a 
strong demand for novel therapeutics for metastatic RCC, as the cancer is highly resistant to 
many existing therapies. Immunotherapies such as anti-PDL-1/PD1 (Weinstock and McDermott, 
2015), anti-CTLA-4  (Seidel, Otsuka and Kabashima, 2018), and targeted therapies such as 
mTOR (Everilimus (Donskov et al., 2020)) and VEGF (Sunitinib (Ravaud et al., 2016)) 
inhibitors, have been shown to reduce tumour progression and overall survival of patients with 







are blocking antibodies targeting the immune checkpoints aimed at enhancing anti-tumour 
immunity in patients: PDL-1 (Nivolumab), PD-1L (Avelumab) and CTLA-4 (Ipilimumab) 
(Motzer et al., 2015, 2018). Unfortunately, response rates and major improvement in overall 
survival have been limited.  
A characteristic of RCC is the cell surface expression of Kidney Injury Molecule-1 (KIM-1). 
KIM-1. Although KIM-1 is known to play an anti-inflammatory and reparative role in acute 
kidney injury, its specific role in RCC (including metastasis) are unclear. Analysis of The Cancer 
Genome Atlas (TCGA) database has shown that >90% of all patients with RCC express KIM-1, 
additionally correlating with overall increased survival (Lee and Gunaratnam, 2019).  
 
Recent findings from our team have demonstrated that tumour associated KIM-1 inhibits 
metastasis. Specifically, we found that KIM-1 expression on murine Renca, and human 786-O 
cells inhibits extravasation and invasion in vitro. KIM-1 expressing human 786-P cells were 
found to have a significant reduction in extravasation capability in an in vivo CAM model. 
Moreover, using an experimental metastasis model, we found that KIM-1 expressing Renca, and 
786-O cells had significantly reduced metastasis to the lungs, independent of adaptive immunity. 
Lastly, we identified two pro-metastatic, invasion, and adhesion genes, Rap1 and RAB27b, that 
may be downregulated by KIM-1. Overall, our findings reveal a novel inhibitory role of KIM-1 
in the metastatic cascade of RCC (Lee and Gunaratnam, 2019). These previous findings suggest 
that KIM-1 may be playing a beneficial role for RCC patients. Further determining the 
pathophysiological role of KIM-1 in RCC progression, may provide new insights into its 







1.4.2 Objective and Hypothesis  
 
The objective of this study was to further understand the pathophysiological role of KIM-1 in 
RCC tumour progression. Based on preliminary clinical findings from TCGA database, we 
hypothesized that KIM-1 expression on RCC inhibited tumour growth and progression. To study 
this, we generated murine RCC Renca cell lines to overexpress KIM-1 (KIM-1pos) or to not 
express KIM-1 (KIM-1neg) through lentiviral transduction, and further investigate in vitro and in 
vivo effects.  
1.4.3 Specific Aims  
 
The aims outlined in the work of this thesis are: 1) To evaluate whether KIM-1 expression alters 
Renca tumour growth within immune competent syngeneic BALB/c mice. 2) Characterize the 
TME of KIM-1pos vs KIM-1neg Renca tumours. And 3) Investigate potential mechanisms and 
downstream targets of KIM-1.  We hypothesize that KIM-1 inhibits primary tumour growth in 
our subcutaneous immune competent model, that KIM-1 alters the TME allowing for a greater 
anti-tumour immune response, and lastly that KIM-1 expression is able to inhibit primary tumour 














2. Methods and Materials 
2.1 Generation of KIM-1 Expressing Stable Cell Line Using Lentiviral 
Particles 
 
A previous master’s student from our laboratory generated our mouse cell lines utilized for the 
aims of this thesis. The mouse Renca adenocarcinoma cell line (Murphy and Hrushesky, 1973)  
known as Renca (CRL-2947) was purchased from American Type Culture Collection (ATCC) 
and transduced with Lentiviral Open Reading Frames (ORF) particles containing empty vector or 
encoding the mouse KIM-1 gene,  Havcr1. The generation of these cell lines are described in 
detail elsewhere. Briefly, lentiviral ORF particles containing a vector coding the mouse KIM-1 
gene transcript (MR203831L3V; Origene, Rockville, MD), was used to implement the 
overexpression of KIM-1 to generate Renca KIM-1pos cells.  Control Lentiviral ORF particles 
containing the same vector without the presence of the mouse KIM-1 gene transcript 
(PS100092V; Origene, Rockville, MD), was used as a control to generate Renca KIM-1neg cells. 
The lentiviral particle concentration used for transduction was determined using multiplicity of 
infection (MOI) ratios. The desired MOI refers to the number of virion infectious particles to the 
number of cells that are needed for stable transduction. The total number of cells per well was 
multiplied by the desired MOI to get the total transducing units (TU). The TU was then divided 
by the viral titre, known as the total TU/ml that is specific to the purchased virus. This 









Methods for the following were performed previously by our team and was essential to the 
success of this project. Renca cells were seeded in a 6-well plate and incubated for 24h at 37°C 
and 5% (v/v) CO2  in complete Dulbecco's Modified Eagle Medium (DMEM; Lonza, 
Walkersville, MD) with 10% (v/v) fetal bovine serum (FBS; Cat No. 12483020, Thermo Fisher 
Scientific, Waltham, MA), 1% (v/v) 200uM L-glutamine (Cat No. 25-030-081, Thermo Fisher 
Scientific, Waltham, MA), 1% (v/v) 100X sodium pyruvate (Cat No. 11360070, Thermo Fisher 
Scientific, Waltham, MA), 1% (v/v) 100X non-essential amino acids (Cat No. 11-140-050, 
Thermo Fisher Scientific, Waltham, MA) until 75% confluency had been reached. After 24 h, 
complete DMEM was aspirated and replaced with fresh complete DMEM, supplemented with 8 
ug/mL polybrene solution (Santa Cruz Biotechnology), along with either mouse-KIM-1 encoded 
lentiviral ORF particles and/or control lentiviral ORF particles. Cells were incubated with 
polybrene solution and lentiviral ORF particles for 24h at 37°C and 5% (v/v) CO2. After 24h, 
medium was aspirated and replaced with fresh complete DMEM. After 72h post-transduction the 
complete DMEM was aspirated and replaced with 1mL of complete DMEM supplemented with 
2ug/ml of puromycin dihydrochloride (Sigma-Aldrich, Oakville, CA) per well. Replacement of 
culture medium containing puromycin dihydrochloride occurred every 2-3 days for two weeks 
post-transduction. After sufficient replication and subculture of positively selected cells, both 
KIM-1pos and KIM-1neg Renca cells were trypsinized (Trypsin-EDTA [0.25%, Cat No. 
25200072, Thermo Fisher Scientific, Waltham, MA]) and collected to confirm KIM-1 gene and 










2.1.2 Cell Culture 
 
Renca cells ( KIM-1pos and KIM-1neg)  were maintained according to culture methods  
recommended by ATCC Renca cells in antibiotic free complete Dulbecco's Modified Eagle 
Medium (DMEM; Lonza, Walkersville, MD) as defined above. Stable cell lines were maintained 
with 2g/mL of puromycin dihydrochloride. Cell culture medium was aspirated and replaced 
every 2-3 days with fresh complete DMEM plus 2g/mL puromycin dihydrochloride where 
required. Renca cells were sub-cultured every 4-5 days using Trypsin-EDTA.  
2.2 Protein Extraction  
 
Cells were seeded in 10cm2 culture dishes (Cat No. 10062-880, VWR, Pennsylvania, USA) with 
complete cell culture medium. Cells were incubated at 37°C and 5% (v/v) CO2 for 24h until 
reaching ~90% confluency. Prior to cell lysis, Radioimmunoprecipitation assay buffer (RIPA 
[RIPA Lysis Buffer System; sc-24948; Santa Cruz Biotechnology]) was prepared by combining 
10ul of sodium orthovanadate, 10l of PMSF solution, and 10ul of protease inhibitor solution for 
every 1mL of complete RIPA buffer needed (sc-24948; Santa Cruz Biotechnology).  Once cells 
have reached ~90% confluency, cell medium was aspirated and cells were washed with cold 1 x 
PBS (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HOP4, 1.47 mM KH2PO4, pH 7.4) for 5 
minutes on ice. Cold 1 x PBS was aspirated, and cells were prepared lysed using. For 100mm 
culture dishes, 1mL complete RIPA buffer was evenly placed on the monolayer of cells while on 
ice for 5 minutes, gently agitating the solution occasionally. Using a cell scrapper, cells were 
collected from the dish and carefully transferred into microcentrifuge tubes. Lysates were then 







supernatants from samples were collected and isolated into fresh microcentrifuge tubes for 
further analysis.  
2.2.1 Western Blot  
 
Whole cell lysates were collected and analyzed for protein purity and concentration using the 
Pierce BCA Protein Assay Kit (Cat No. 23225, Thermo Fisher Scientific, Waltham, MA). 
Protein concentrations were determined and compared to the concentrations of protein standards 
provided with the kit. Lysate samples were diluted with appropriate amounts of H2O, to generate 
a total concentration of 50g of protein per sample. Loading dye was prepared by combining 
190l 6x sodium dodecyl sulphate (SDS) protein loading buffer (Laemmli buffer) with 10l 
of -mercaptoethanol. Subsequently, 6l of prepared loading dye solution were added to each 
sample to reduce disulphide bonds. Samples were then boiled for 5 minutes at 95°C to further 
denature protein structures. Samples were then loaded onto 10% SDS-polyacrylamide gels. 
Protein samples were then separated based on charge-to-mass ratio and then transferred onto a 
polyvinylidene difluoride membrane (Millipore, Billerica, MA) for 50 minutes at 90 V (Bio-Rad, 
Hercules, CA). After 50 minutes, membranes were blocked with a 3% (w/v) BSA (bovine serum 
albumin; Cat No. AD0023, Bio Basic, Markham, ON) solution made in 1 x TBST (Tris-buffered 
saline, in 1mL of 0.2% Tween-20Cat No. BP337-500, Fisher Bioreagents, Waltham, MA). 
Membranes were then incubated overnight at 4°C on a rotational shaker with either goat anti- 
mouse KIM-1 primary antibody (1:2000; Cat No. AF1817, R& D Systems, Minneapolis, MN) or 
anti-human KIM-1 (AKG;  [Han et al., 2002]) targeting the extracellular domain of KIM-1. 
Glyceraldehyde phosphate dehydrogenase (GAPDH) was used (loading control) was detected 







incubation, membranes were then washed 4 times on a rotational shaker in 1 x TBST with 
changes every 7 minutes. Membranes were then incubated with appropriate secondary antibodies 
conjugated with horseradish peroxidase (1:20000; Jackson Immunoresearch Laboratories, West 
Grove, PA) in 3% BSA blocking buffer for 1h in the dark, at room temperature. After secondary 
antibody incubation and washing in 1 x TBST for 5 minutes for 3 times, proteins were then 
visualized using Luminata Forte Western HRP Substrate (EMD Milipore) and developed on the 
Licor C-digital imaging device. Western blot images were captured using Image Studio Lite.  
2.3 RNA Isolation 
 
Cell and tissue RNA were extracted on ice using TriZol Isolation Reagent (Cat No. 15596018; 
Life Technologies) using approximately 500l-1mL per sample depending on cell confluency 
and/or tissue size, respectively. For every 500l of TriZol, 100l of chloroform was added to 
facilitate phase separation. Samples were briefly vortexed and incubated on ice for 10 minutes 
before centrifugation at ~ 12,000 x g for 20 minutes at 4°C. After centrifugation and phase 
separation had occurred, the aqueous layer was removed carefully and placed into a fresh 
microcentrifuge tube. For every 500l of TriZol, 100l of isopropanol was added to the aqueous 
layer to facilitate precipitation of RNA. Samples were briefly vortexed and incubated on ice for 
10 minutes before centrifugation at ~ 12,000 x g for 10 minutes at 4°C. Supernatants were 
removed from the samples and discarded. Pellets were washed with 70% ethanol (EtOH) diluted 
in Diethyl Pyrocarbonate (DEPC) -treated H2O (RNase free water) and centrifuged at ~ 7,500 x g 
for 5 minutes at 4°C. Supernatant was removed from samples and discarded. RNA pellets were 
resuspended in DEPC-treated H2O and heated in a water bath at 56°C for 10 minutes. RNA was 







MulltishkanTM GO Microplate Spectrophotometer; Thermo Fisher Scientific, Waltham, MA). 
One microliter of total RNA was placed onto Microplate and absorbances were used to calculate 
purity and concentration of RNA. One microgram of total RNA was combined with 4L of 
qSCRIPT cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) to synthesize cDNA. The 
reaction was facilitated using a MyCyclerTM Thermal Cycler (Bio-Rad, Hercules, CA). cDNA 
was further stored at -20°C until further analyzation.  
2.3.1 Real Time Quantitative PCR (RT-qPCR) 
 
cDNA samples were used to perform RT-qPCR using SYBR green reagents (Thermo Fisher 
Scientific, Waltham, MA). Reaction mixtures were placed in a v-shaped 96-well plate, each well 
containing 10L of SYBR green, 4.6L of DEPC-treated water, 5l of diluted cDNA in DEPC-
treated water (ratio 1:10), and 0.2L of both 10M forward and reverse strand primers made by 
myself. Various primers were used to detect varying gene transcriptions in both cell lines and 
tissues shown in Table 1. Target genes were normalized using GAPDH to counterbalance any 
PCR variations present. Relative gene expression was calculated using 2- CT method.  
2.3.2 RNA Sequencing   
 
Renca cell line preparation for RNA sequencing was performed by Brad Shrum. Previously 
generated data showing discrepancies between our Renca cells [ KIM-1pos and KIM-1neg] (Lee 
and Gunaratnam, 2019), was re-analyzed for this project. RNA sequencing was performed by 
London Genomics Centre with the help of Dr. Rob Hegele at the Robarts Research Institute at 
Western University. RNA was extracted and isolated, with subsequent cDNA synthesis 
performed as described above on both KIM-1pos and KIM-1neg Renca cell lines. Illumina 







NextSeq 500 sequencer (Illumina Inc., San Diego, CA). All sequence data was generated and 
analyzed by Partek Flow Software (Partek Inc., St. Louis, MO). Stringencies for data analysis 
was instilled within the bioinformatic pipeline to only compare genes with a p-value < 0.05, and 
to exclude fold changes between 1.5 and -1.5. Differential genes were analyzed through gene 
enrichments; allowing for the grouping of like genes that comply to a specific cellular function, 
as well as gene pathways. Bioinformatic pipelines were further specified by exploring for 
functional cellular differences within both gene enrichments, and gene pathways.  
2.4 The Human Cancer Genome Atlas (TCGA) Database 
 
All raw TCGA patient data was extrapolated and organized into a working excel spreadsheet by 
colleague Audrey Champagne. KIPAN patient database was used to complete human RCC and 
KIM-1 analyses. KIPAN database contains patient information from those diagnosed with 
ccRCC (KIRC or Kidney Clear Cell Carcinoma), pRCC (KIRP or Kidney Papillary Carcinoma), 
and Chromophobe RCC (KICH or Chromophobe Carcinoma). Working spreadsheet was then 
filtered to select data based upon analyses needed. Data was then transferred into 
GraphPad/Prism 8 in order to perform statistical analyses and generate graphical representations.  
 
2.5 Mice  
Animal protocol (2018-147) outlining all the studies contained in this thesis were approved by 
Western University's Animal Care Committee and in compliance with the guidelines set by 
Canadian Council of Animal Care. Female wild-type (WT) BALB/c mice were purchased from 
Charles River Laboratory (Wilmington, MA). Female mice are the common model to use for 







comparison to male mice (Hu et al., 2009). All mice were kept in shoebox cages with easy 
access to water and mouse chow pellets. Immune-deficient recombinase-activating gene (Rag 1-/-
) null mice were purchased from Jackson Laboratory (Bar Harbor, ME) and housed in the West 
Valley pathogen-free barrier facility at Western University. These mice were kept in shoebox 
microisolator cages with easy access to water and mouse chow pellets. Mouse holding rooms 
were maintained at a constant temperature of 22°C with timed 12 h light and 12 h dark periods.  
 
Experimental mice were monitored every 2-3 days for health and behavioral monitoring. All 
physiological and behavioral changes were monitored and recorded for all experimental animals. 
After experiments were complete, all mice were euthanized using CO2. Collection of samples 
needed per experiments occurred post-mortem. Mouse holding rooms were maintained at a 
constant temperature of 22°C with timed 12 h light and 12 h dark periods.  
 
2.6. Experimental Tumour Models  
2.6.1 Subcutaneous Model of RCC Tumours  
 
To study tumour growth of RCC cells with the overexpression of KIM-1 (Renca KIM-1pos) or 
the absent expression of KIM-1 (Renca KIM-1neg) – Renca cell lines were injected into immune 
competent BALB/c mice. Prior to injections, Renca cells were cultured in 15cm dishes at a 
seeding concentration of 1 x 106cells/mL in complete DMEM. Stable expression of the 
transduced cell lines was maintained with 2g/mL of puromycin dihydrochloride. Medium was 
aspirated and replaced with fresh complete DMEM and puromycin dihydrochloride every 2-3 







with 10mL of warmed 1xPBS, and subsequently replaced with 5mL of Trypsin-EDTA  for 5 
minutes in 37°C, 5% (v/v) CO2 incubator. 10mL of complete DMEM was then added to cells to 
neutralize trypsin. Cells were then spray washed to remove any adherent cells from the culture 
dish surface. Collected cells were then centrifuged at 21°C, 400 x g, for 3 minutes. After 
centrifugation, the supernatant was aspirated and discarded, and cell pellets were then 
resuspended in complete DMEM in preparation for cell counting. Cells were counted using a 1:1 
dilution; 10L of trypan blue (0.4%) (Cat No. 97063-702, VMR International) with 10L of 
suspended cells onto a hemocytometer (Fisher Scientific, Waltham, MA). Cell viability was 
assessed using Trypan blue exclusion and cell a viability of >95% was observed before injection. 
After determining the total cell number, cells were resuspended at a concentration of 1x106 
cells/100L in a 1:1 ratio of 1xPBS and Corning MatrigelTM growth factor reduced (GFR) 
Membrane Matrix (Cat No. CB-40230C, Thermo Fisher Scientific, Waltham, MA). Cells in PBS 
and MatrigelTM were kept on ice to avoid solidification of matrix solution. Mice were sedated 
using 2% isoflurane for medium depth anesthesia following standard operating procedures prior 
to and during injections. Renca cells were resuspended at 1 x 106 cells/100L in either 1 x PBS 
alone (No MatrigelTM) or in a 1:1 dilution of 1 x PBS with Corning (GFR) MatrigelTM Membrane  
at a volume of 100L/injection.  One hundred microliters of each cell line were placed into an 
intermediary microcentrifuge tube, and subsequently drawn up into an 1/2 inch 28-gauge insulin 
syringe (Becton Dickinson, Franklin Lakes, NJ). Cells were either injected bilaterally, where 
Renca KIM-1pos and Renca KIM-1neg cells were injected into opposite flanks of the same mouse, 
or cells were injected unilaterally where only one cell line was given per mouse. Prior to 
injection, needles were inserted bevel up under the skin, and gently moved around to remove 







shape. Mice were monitored every day for the first 72h post injection, and then every 3-4 days 
afterwards for a duration of 21 days. Mice were then euthanized using a CO2 chamber, and 
tumours were removed using sterile surgical instruments, and collected for further analysis.  
2.6.2 Renal Orthotopic Model 
 
To study tumour growth of Renca KIM-1pos vs Renca KIM-1neg cells in a clinically relevant 
model of RCC – Renca cells were injected directly into the kidney. Specifically, either Renca 
KIM-1pos or Renca KIM-1neg cells were injected orthotopically into the subcapsular region of the 
left kidney of 6-10-week-old female WT BALB/c mice. Prior to injections, Renca cells were 
cultured, collected, and counted using the methods as described above. After determining the 
total cell number, cells were resuspended at a concentration of 2.5 x 105 cells/100L in a 1:1 
ratio of 1xPBS and Corning MatrigelTM GFR Membrane Matrix. Cells in PBS and MatrigelTM 
were kept on ice to avoid solidification of matrix solution. Mice were given slow-release 
buprenorphine (0.6mg/kg, Chiron Compounding Pharmacy, Guelph, ON) analgesics, and 
subsequently isoflurane sedation prior to surgical injections. Mouse fur was then shaved at the 
region of interest on the left flank, and surgical area was sterilized with iodine solution and 70% 
ethanol. Skin barrier and muscle layer were incised using sterile surgical instruments. Left 
kidneys were exposed and 30l of cells in MatrigelTM suspension were injected into the 
subcapsular region of the left kidney. All incisions were closed using sutures and staples 
according to our standard operating procedures outlined in animal our protocol. Mice were kept 
under a heat lamp until conscious and monitored 24 h post-injection, and every 2 days following. 
After 21 days, mice were euthanized using a CO2 chamber, tumour bearing kidneys and lungs 








2.7 Tumour Immunofluorescence Microscopy 
2.7.1 Sample Preparation 
 
All tissue samples were fixed in Periodate-Lysine-Paraformaldehyde (PLP) solution, made one 
day before use. Solution was made by first preparing a phosphate buffer containing 3:1 parts 
monobasic sodium phosphate and dibasic sodium phosphate diluted in double distilled H2O 
(ddH2O). Phosphate buffer was autoclaved and cooled to room temperature prior to preparing 
complete fixative solution. Once phosphate buffer reached room temperature, L-Lysine (>98%, 
Cat No. L5501-25G, Sigma-Aldrich, Oakville, CA) and Paraformaldehyde (PFA, Cat No. 
PB0684.SIZE.500g, Bio Basic, Markham, ON) were diluted in ddH2O and combined. Sodium 
Periodate (>99.8%, Cat No. 311448-100G, Sigma-Aldrich, Oakville, CA) was then added to 
mixture. Using the prepared phosphate buffer, the total volume was then brought up to 500mL or 
1L depending on how much solution was needed. PLP was kept at 4°C, in the dark until use 
(Appendix A 2).  
 
Subcutaneous and renal subcapsular experimental tumours were both collected to analyze 
immune infiltration using immunofluorescence. After euthanization, tissues were collected in 
15mL Falcon Centrifuge tubes (Cat No. 14-959-49B, Thermo Fisher Scientific, Waltham, MA), 
containing 10mL of PLP. Samples incubated in PLP for a maximum of 24 h, on a rotational 
shaker at 4°C, in the dark. After 24 h, samples were removed from PLP and gently rinsed with 
phosphate buffer before subjecting tissues to a sucrose gradient. Sucrose solutions were prepared 
the same day to ensure no bacterial contaminations occurred. Sucrose gradients were prepared 







30% sucrose (>99.5%, Cat No. S7903-250G, Sigma-Aldrich, St. Louis, MO). All samples were 
placed in each gradient beginning at 10%, then subsequently 20%, and 30%, for one hour at a 
time or until tissues sank. After completing the three sucrose gradient steps, tissues were 
removed from sucrose and pat dried. A freezing bath was prepared using a metal tray placed in a 
styrofoam box containing dry ice with 10mL of 95% (v/v) ethanol. Approximately  5mL of 2-
Methylbutane Reagent (>99%) (Cat No. M32631-4L, Sigma-Aldrich, Oakville, CA) was added 
to the metal tray and allowed to reach the appropriate freezing temperature. Tissues were then 
placed in OCT compound (Cat No. 23730571, Thermo Fisher Scientific, Waltham, MA) in tissue 
cassettes. Tissues completely submerged in OCT compound within cassettes were placed onto 
metal tray until OCT compound froze around tissues. Cassettes were then wrapped in cling wrap 
and covered with tin foil prior to storage in the -80°C to avoid samples drying out.  
2.7.2 Co-Immunofluorescence 
 
Frozen OCT blocks containing tissue samples were sent off to Weihua Liu in the Department of 
Pathology at The University of Western Ontario. Samples were removed from histology tissue 
cassettes and placed onto a cryostat and sliced at a size of 7-10 microns. Each sample is then 
placed onto a positively charged glass slide (Cat No. 22-037-246, Fisher Scientific, Waltham, 
MA) and mounted appropriately. Fluorophore conjugated antibodies were applied to samples - 
CD3+ (SP7) (1:200, Cat No. NB600-1441SS, Novus Biologicals), CD4+ (1:200, Cat No. 
MABF575, Millipore Sigma, Burlington, MA), and CD8+ (1:400, Cat No. 100727, Bio Legend, 
San Diego, CA) to analyze co-immunofluorescence (CD3+, CD3+CD4+, and CD3+ CD8+). 
Tumour samples were analyzed for immune infiltrate population frequency and distribution 
using Cell Counter plugin in Fiji (ImageJ) Software, normalized to measured areas of focus (per 









Tissue samples that were subjected to immunohistochemical staining were collected from mice, 
and directly placed into 15mL Falcon tubes (Cat No. 14-959-49B, Thermo Fisher Scientific, 
Waltham, MA) containing 10% formalin buffered solution (Cat No. HT501128-4L, Sigma-
Aldrich, Oakville, CA). Tissue samples were incubated in 10% formalin for 72 h for tissue 
fixation. After 72 h, samples were moved from 10% formalin to 70% ethanol prior to analysis. 
Samples were then embedded in paraffin blocks within tissue cassettes. After hardening 
occurred, embedded tissues were sliced at 7-10 microns, and placed onto a positively charged 
glass slide. Samples were mounted properly and stained with either hematoxylin and eosin 
(H&E) or Masson’s Trichrome staining for further analysis.  
 
Quantification of histological sections of KIM-1pos and KIM-1neg Renca tumour capsules were 
measured using brightfield microscope analyzing for distance width measurements using NIS-
Elements Nikon Software. All tumour capsules were measured at 100x and normalized to total 
visualized area imaged by the microscope software. Tumour capsule measurements were 
evaluated using distance between two points; from the inner-most to the outer-most collagen 
layer of the capsule. Capsules were measured at five randomized locations throughout each 
tumour sample, and widths were averaged for final measurements. 
2.8 Statistical Analysis   
All data is presented as a mean ± standard error of the mean (SEM). Normality was assessed 
using normality and lognormality tests.  Between group differences in standard error of the 
means (SEM) were assessed using Student’s t- or Kruskal-Wallis tests for parametric and 







compared with log-rank test. Normality Lognormality statistical analysis was used to compare 
matched normal vs adjacent tumour tissue from TCGA patient database. A two-tailed alpha 
<0.05 was considered statistically significant. Statistical analyses were performed using 
GraphPad Prism, version 8.  
2.9 Sample Size Calculation 
 
Sample size calculation for tumour growth studies was calculated prior to experiments to 
determine proper N to observe significance. N mice in each group would provide >=80% power 
to detect at least a 30% difference in tumour growth between groups, two-sided alpha = 0.05.  N 
mice per group would provide >=80% power to detect at least a difference of at least xx standard 
























3. 1 KIM-1 (Havcr1) mRNA is expressed at all stages of RCC and increases 
overall patient survival  
 
To investigate how KIM-1 expression may impact the survival of patients diagnosed with RCC, 
we utilized The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/tcga). KIPAN 
patient database including data from ccRCC, pRCC, and Chromophobe RCC patients was 
extracted. For our analysis, the KIRC (Kidney Clear Cell Carcinoma) and KIRP (Kidney 
Papillary Carcinoma) databases were combined due to KIM-1 upregulation being found in only 
ccRCC and pRCC patients (Zhang et al., 2014). I analyzed ccRCC or pRCC patient data in 
correlation with tumour associated KIM-1 (Havcr1) mRNA expression. First, I analyzed 
differences of KIM-1 expression between affected RCC tumours, and adjacent unaffected or 
normal tissue. Results showed that KIM-1 mRNA expression was significantly increased within 
tumours compared to normal adjacent tissue (Fig 1A). I then stratified patients according to the 
American Joint Committee on Cancer (AJCC) tumour-node-metastasis (TNM) staging system 
(Stages 1 to 4) to determine if KIM-1 expression varied with stage (The American Joint 
Committee on Cancer (AJCC), 2017).  Compared to normal adjacent tissue, the KIM-1 mRNA 
expression level was significantly increased in tumours at all stages of RCC (Fig 1B). Finally, 
patients with tumours having KIM-1 expression in the top 50th percentile had significantly 
improved survival compared to patients with tumours having KIM-1 expression below the 50th 
percentile in a KIRC and KIRP combined analyses (median survival = 25% vs. 50%, 







were completed to evaluate discrepancies between tumour types. KIM-1 expression was found to 
significantly increase overall survival of KIRC patients (Fig 1D), but not KIRP patients (Fig 1E).  
 
  




























Figure 1. TCGA RNA Sequencing data reveals HAVCR1 (KIM-1) mRNA is expressed at all 
stages of RCC and increased expression correlates to increased survival of KIRC (Kidney Clear 
Cell Carcinoma) and KIRP (Kidney Papillary Carcinoma) patients. 
A. Comparison of KIM-1 mRNA expression within non-paired normal adjacent tissue vs tumour 
tissue of KIRC and KIRP RCC patients (Normal: n = 129, Tumour: n = 823) (****, P<0.0001, 
Mann-Whitney t-test). B. KIM-1 mRNA expression in KIRC and KIRP RCC tumour stages vs 
normal adjacent tissue (Normal: n = 129, I: n = 439, II: n = 78, III: n = 175, IV: n = 99) (****, 
P<0.0001, Kruskal-Wallis statistical analysis). C. Overall KIRC and KIRP patient survival vs 
KIM-1 mRNA expression using 50% low/high expression cut-offs (Low: n = 376, High: n = 
441) (**, p = 0.0059; Kaplan-Meier statistical analysis). D. Overall KIRC patient survival vs 
KIM-1 mRNA expression using 50% low/high expression cut-offs (Low: n = 259, High: n = 
272) (**, p = 0.0019; Kaplan-Meier statistical analysis). E. Overall KIRP patient survival vs 
KIM-1 mRNA expression using 50% low/high expression cut-offs (Low: n = 117, High: n = 








3.2 Expression of several collagen genes is increased within human RCC 
tumour tissue, in comparison to normal adjacent tissue 
 
Extracellular matrix (ECM) and collagen properties are widely studied in terms of its effects on 
tumour progression and metastasis (Fang et al., 2014). Thus, I investigated the correlation 
between collagen and KIM-1 expression in RCC patients with ccRCC and pRCC from TCGA. 
Collagen genes of interest; COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1 were selected 
based off previous research of collagen in RCC (Wan et al., 2015; Xu et al., 2017; Majo et al., 
2020).  First, I analyzed the expression of the above collagen genes and compared their 
expression in RCC tumour tissue vs normal adjacent tissue for each patient. Results showed that 
COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1 mRNA expression were all significantly 
increased within RCC tumour tissues compared to matched normal adjacent tissues (Fig 2A-E). 
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Figure 2. TCGA RNA Sequencing database reveals increased collagen mRNA expression in 
RCC tumour tissue vs normal adjacent tissue using KIRC (Kidney Clear Cell Carcinoma) and 
KIRP (Kidney Papillary Carcinoma) patient databases. 
Paired comparison of normal adjacent tissue vs matched patient tumour tissues reveals several 
collagen genes A. Col1A1, B. Col1A2, C. Col6A1, D. Col6A2 and E. Col23A1 mRNA 
expression increased in RCC tumour tissues (n=104/group) (****, P<0.0001; Normality 








3. 3 mRNA expression of KIM-1 vs serval collagen genes, have no clear 
correlation in human RCC patients 
 
To investigate the relationship between KIM-1 and collagen gene mRNA expression within 
human RCC patients, I analyzed our previously used collagen genes of interest (COL1A1, 
COL1A2, COL6A1, COL6A2, and COL23A1) along with 29 genes selected from a group of 
genes termed tumour matrisome index (TMI) by Su Bin Lim and team (Lim et al., 2019). The 
TMI was previously used to perform a multi-component analysis of ECM genes in a pan-cancer 
study to elucidate differential tumour immune responses. Using our previous genes of interest as 
well as the 29 genes within the TMI from Su Bin Lim, I analyzed correlations between collagen 
genes vs KIM-1 mRNA expression within human RCC patients (Lim et al., 2019) (Fig 3A). 
TCGA RNA-seq data from KIPAN databases (KIRC, KIRP and KICH) were used in order to 
correlate comparative mRNA expression levels. Tumour KIM-1 expression in the top 25th 
percentile, and bottom 25th percentile were compared using Spearman’s rank order correlation 
co-efficient to elucidate whether each collagen gene had a negative or positive correlation to 
KIM-1 (Havcr1). Results showed many correlations between the signature and KIM-1, yet no 
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Tumour Matrisome Index (TMI) 



































Variables HAVCR1 ABI3BP ADAMTS8 CD36 CHRDL1 COL10A1 COL11A1 COL6A6 CPB2 CTHRC1 CXCL13 CXCL2 FCN3 GREM1 HHIP IL6 LPL MAMDC2 MMP1 MMP12 OGN PCOLCE2 S100A12 S100A2 SFTPA2 SFTPC SFTPD SPP1 TNNC1 WIF1 COL1A1 COL1A2 COL23A1 COL6A1 COL6A2
HAVCR1 1 0.428 -0.089 0.072 -0.068 -0.093 0.007 -0.173 -0.026 0.114 0.149 0.142 -0.029 -0.115 0.019 -0.133 -0.104 -0.061 -0.070 -0.122 -0.157 0.151 0.055 -0.364 -0.031 -0.100 -0.129 0.275 -0.391 -0.023 0.100 0.085 0.406 -0.203 0.096
ABI3BP 0.428 1 0.065 0.000 0.083 -0.022 0.104 -0.020 -0.034 0.135 -0.003 0.236 -0.083 -0.023 0.162 -0.017 -0.075 0.086 -0.096 -0.066 -0.045 0.062 0.050 -0.097 -0.035 -0.157 0.035 0.206 -0.183 0.033 0.073 0.107 0.314 -0.078 0.136
ADAMTS8 -0.089 0.065 1 -0.073 0.332 0.175 0.132 0.229 0.076 -0.072 -0.118 0.139 0.058 0.306 0.316 0.191 0.172 0.303 -0.032 -0.024 0.398 0.062 -0.007 0.304 0.122 0.013 0.289 -0.043 0.369 0.281 0.021 0.100 -0.027 0.017 0.122
CD36 0.072 0.000 -0.073 1 -0.213 0.163 0.254 0.005 0.024 0.493 0.421 0.140 0.708 0.161 -0.137 0.304 0.570 -0.102 0.452 -0.052 0.250 0.496 0.461 -0.540 -0.032 -0.258 0.268 -0.527 -0.394 -0.208 0.452 0.494 0.556 0.140 0.424
CHRDL1 -0.068 0.083 0.332 -0.213 1 0.362 0.240 0.242 0.071 0.006 0.001 0.112 -0.118 0.513 0.351 0.337 0.070 0.532 0.024 0.254 0.434 0.098 -0.017 0.374 0.057 0.032 0.072 0.127 0.436 0.349 0.059 0.146 -0.240 -0.018 0.020
COL10A1 -0.093 -0.022 0.175 0.163 0.362 1 0.719 0.239 0.044 0.491 0.336 0.083 0.238 0.596 0.233 0.469 0.149 0.256 0.283 0.281 0.522 0.229 0.161 0.090 0.048 -0.025 0.005 -0.074 0.103 0.192 0.607 0.614 0.025 0.354 0.427
COL11A1 0.007 0.104 0.132 0.254 0.240 0.719 1 0.125 0.079 0.619 0.370 0.218 0.275 0.541 0.196 0.507 0.101 0.193 0.365 0.293 0.368 0.224 0.205 -0.015 0.038 -0.131 0.065 -0.083 -0.063 0.043 0.715 0.687 0.207 0.428 0.584
COL6A6 -0.173 -0.020 0.229 0.005 0.242 0.239 0.125 1 -0.003 0.008 -0.019 -0.037 -0.013 0.285 0.208 0.158 0.121 0.213 0.054 0.090 0.327 0.045 -0.105 0.157 0.006 -0.029 0.039 -0.141 0.269 0.181 0.102 0.120 -0.172 0.102 0.051
CPB2 -0.026 -0.034 0.076 0.024 0.071 0.044 0.079 -0.003 1 0.127 0.122 0.104 0.050 0.067 0.063 0.065 0.039 0.015 0.046 0.037 0.054 0.062 0.023 0.029 0.059 -0.017 0.035 0.024 -0.040 0.019 0.057 0.091 0.078 -0.001 0.099
CTHRC1 0.114 0.135 -0.072 0.493 0.006 0.491 0.619 0.008 0.127 1 0.577 0.289 0.373 0.383 -0.008 0.456 0.080 -0.028 0.460 0.224 0.240 0.308 0.381 -0.282 0.026 -0.243 0.057 -0.179 -0.341 -0.155 0.779 0.732 0.484 0.446 0.721
CXCL13 0.149 -0.003 -0.118 0.421 0.001 0.336 0.370 -0.019 0.122 0.577 1 0.213 0.367 0.274 -0.079 0.334 0.029 -0.221 0.313 0.195 0.182 0.349 0.335 -0.343 -0.009 -0.175 -0.066 -0.224 -0.297 -0.111 0.537 0.492 0.439 0.275 0.512
CXCL2 0.142 0.236 0.139 0.140 0.112 0.083 0.218 -0.037 0.104 0.289 0.213 1 0.109 0.136 0.084 0.458 0.058 0.052 0.104 0.184 0.050 0.204 0.288 0.009 0.061 -0.161 0.129 0.087 -0.117 0.028 0.225 0.203 0.325 0.111 0.305
FCN3 -0.029 -0.083 0.058 0.708 -0.118 0.238 0.275 -0.013 0.050 0.373 0.367 0.109 1 0.132 -0.035 0.284 0.502 -0.105 0.313 -0.052 0.332 0.540 0.423 -0.327 -0.059 -0.161 0.307 -0.445 -0.238 -0.109 0.394 0.443 0.491 0.186 0.399
GREM1 -0.115 -0.023 0.306 0.161 0.513 0.596 0.541 0.285 0.067 0.383 0.274 0.136 0.132 1 0.299 0.542 0.217 0.364 0.361 0.324 0.635 0.200 0.169 0.160 0.126 -0.067 0.104 -0.115 0.243 0.217 0.483 0.530 -0.011 0.172 0.364
HHIP 0.019 0.162 0.316 -0.137 0.351 0.233 0.196 0.208 0.063 -0.008 -0.079 0.084 -0.035 0.299 1 0.179 0.119 0.308 -0.021 0.107 0.338 0.174 -0.013 0.216 0.041 -0.027 0.139 0.082 0.255 0.269 0.136 0.192 -0.030 0.019 0.127
IL6 -0.133 -0.017 0.191 0.304 0.337 0.469 0.507 0.158 0.065 0.456 0.334 0.458 0.284 0.542 0.179 1 0.243 0.206 0.386 0.345 0.351 0.327 0.314 0.096 0.110 -0.098 0.218 -0.094 0.040 0.105 0.474 0.490 0.104 0.253 0.400
LPL -0.104 -0.075 0.172 0.570 0.070 0.149 0.101 0.121 0.039 0.080 0.029 0.058 0.502 0.217 0.119 0.243 1 0.170 0.258 -0.023 0.376 0.379 0.254 -0.136 0.035 -0.076 0.304 -0.400 0.018 0.020 0.118 0.237 0.169 -0.068 0.100
MAMDC2 -0.061 0.086 0.303 -0.102 0.532 0.256 0.193 0.213 0.015 -0.028 -0.221 0.052 -0.105 0.364 0.308 0.206 0.170 1 -0.018 0.097 0.407 -0.006 -0.039 0.322 0.066 0.049 0.058 0.058 0.341 0.262 0.049 0.140 -0.269 -0.062 -0.020
MMP1 -0.070 -0.096 -0.032 0.452 0.024 0.283 0.365 0.054 0.046 0.460 0.313 0.104 0.313 0.361 -0.021 0.386 0.258 -0.018 1 0.204 0.246 0.294 0.303 -0.142 0.031 -0.147 0.166 -0.251 -0.118 -0.072 0.430 0.412 0.225 0.141 0.314
MMP12 -0.122 -0.066 -0.024 -0.052 0.254 0.281 0.293 0.090 0.037 0.224 0.195 0.184 -0.052 0.324 0.107 0.345 -0.023 0.097 0.204 1 0.109 0.054 0.108 0.160 0.027 0.055 -0.095 0.136 0.115 0.046 0.273 0.255 -0.084 0.214 0.161
OGN -0.157 -0.045 0.398 0.250 0.434 0.522 0.368 0.327 0.054 0.240 0.182 0.050 0.332 0.635 0.338 0.351 0.376 0.407 0.246 0.109 1 0.313 0.186 0.104 0.043 -0.076 0.150 -0.290 0.291 0.260 0.392 0.475 0.053 0.149 0.298
PCOLCE2 0.151 0.062 0.062 0.496 0.098 0.229 0.224 0.045 0.062 0.308 0.349 0.204 0.540 0.200 0.174 0.327 0.379 -0.006 0.294 0.054 0.313 1 0.401 -0.281 -0.036 -0.206 0.226 -0.236 -0.141 0.106 0.293 0.360 0.441 0.043 0.303
S100A12 0.055 0.050 -0.007 0.461 -0.017 0.161 0.205 -0.105 0.023 0.381 0.335 0.288 0.423 0.169 -0.013 0.314 0.254 -0.039 0.303 0.108 0.186 0.401 1 -0.189 0.038 -0.135 0.126 -0.205 -0.177 -0.081 0.317 0.342 0.410 0.103 0.325
S100A2 -0.364 -0.097 0.304 -0.540 0.374 0.090 -0.015 0.157 0.029 -0.282 -0.343 0.009 -0.327 0.160 0.216 0.096 -0.136 0.322 -0.142 0.160 0.104 -0.281 -0.189 1 0.068 0.158 0.038 0.258 0.585 0.323 -0.251 -0.247 -0.555 -0.024 -0.240
SFTPA2 -0.031 -0.035 0.122 -0.032 0.057 0.048 0.038 0.006 0.059 0.026 -0.009 0.061 -0.059 0.126 0.041 0.110 0.035 0.066 0.031 0.027 0.043 -0.036 0.038 0.068 1 0.168 0.126 0.051 0.012 0.049 -0.020 -0.028 -0.003 -0.047 0.027
SFTPC -0.100 -0.157 0.013 -0.258 0.032 -0.025 -0.131 -0.029 -0.017 -0.243 -0.175 -0.161 -0.161 -0.067 -0.027 -0.098 -0.076 0.049 -0.147 0.055 -0.076 -0.206 -0.135 0.158 0.168 1 -0.091 0.167 0.177 0.038 -0.164 -0.174 -0.299 -0.013 -0.226
SFTPD -0.129 0.035 0.289 0.268 0.072 0.005 0.065 0.039 0.035 0.057 -0.066 0.129 0.307 0.104 0.139 0.218 0.304 0.058 0.166 -0.095 0.150 0.226 0.126 0.038 0.126 -0.091 1 -0.182 0.057 0.019 0.027 0.094 0.191 -0.001 0.114
SPP1 0.275 0.206 -0.043 -0.527 0.127 -0.074 -0.083 -0.141 0.024 -0.179 -0.224 0.087 -0.445 -0.115 0.082 -0.094 -0.400 0.058 -0.251 0.136 -0.290 -0.236 -0.205 0.258 0.051 0.167 -0.182 1 0.056 0.089 -0.197 -0.224 -0.218 -0.130 -0.206
TNNC1 -0.391 -0.183 0.369 -0.394 0.436 0.103 -0.063 0.269 -0.040 -0.341 -0.297 -0.117 -0.238 0.243 0.255 0.040 0.018 0.341 -0.118 0.115 0.291 -0.141 -0.177 0.585 0.012 0.177 0.057 0.056 1 0.311 -0.249 -0.188 -0.495 -0.056 -0.282
WIF1 -0.023 0.033 0.281 -0.208 0.349 0.192 0.043 0.181 0.019 -0.155 -0.111 0.028 -0.109 0.217 0.269 0.105 0.020 0.262 -0.072 0.046 0.260 0.106 -0.081 0.323 0.049 0.038 0.019 0.089 0.311 1 -0.099 -0.047 -0.219 -0.132 -0.116
COL1A1 0.100 0.073 0.021 0.452 0.059 0.607 0.715 0.102 0.057 0.779 0.537 0.225 0.394 0.483 0.136 0.474 0.118 0.049 0.430 0.273 0.392 0.293 0.317 -0.251 -0.020 -0.164 0.027 -0.197 -0.249 -0.099 1 0.911 0.419 0.571 0.794
COL1A2 0.085 0.107 0.100 0.494 0.146 0.614 0.687 0.120 0.091 0.732 0.492 0.203 0.443 0.530 0.192 0.490 0.237 0.140 0.412 0.255 0.475 0.360 0.342 -0.247 -0.028 -0.174 0.094 -0.224 -0.188 -0.047 0.911 1 0.409 0.484 0.756
COL23A1 0.406 0.314 -0.027 0.556 -0.240 0.025 0.207 -0.172 0.078 0.484 0.439 0.325 0.491 -0.011 -0.030 0.104 0.169 -0.269 0.225 -0.084 0.053 0.441 0.410 -0.555 -0.003 -0.299 0.191 -0.218 -0.495 -0.219 0.419 0.409 1 0.107 0.509
COL6A1 -0.203 -0.078 0.017 0.140 -0.018 0.354 0.428 0.102 -0.001 0.446 0.275 0.111 0.186 0.172 0.019 0.253 -0.068 -0.062 0.141 0.214 0.149 0.043 0.103 -0.024 -0.047 -0.013 -0.001 -0.130 -0.056 -0.132 0.571 0.484 0.107 1 0.712







Figure 3. Correlogram examining the correlation between tumour KIM-1 and collagen 
signatures mRNA expression using TCGA KIPAN patient databases. 
A. List of TMI genes extrapolated from Su Bin Lim and team used in correlation analysis (Lim 
et al., 2019), along with several collagen genes of interest (COL1A1, COL1A2, COL6A1, 
COL6A2 and COL23A1). B. Correlogram of Spearman’s correlation matrix comparing collagen 
and TMI signature and collagen genes to KIM-1 mRNA expression levels in human RCC 
patients. Correlation co-efficient ranging from +1 to -0.5 were plotted and used to create visual 
comparative heat map. Perfect correlations noted as +1 or -1, for both positive and negative 
correlations to KIM-1 expression, respectively. Each plot in correlogram represents a gene 
correlation to KIM-1, for each patient analyzed (KIPAN (total): n = 1019: KIRC: n = 606, KIRP: 




3. 4 KIM-1 expression on RCC cell does not alter their tumorigenic potential 
when injected bilaterally into BALB/c mice. 
 
To investigate the role of KIM-1 expression on the growth of RCC tumours, we injected 1 x 106 
KIM-1pos and KIM-1neg Renca cells into the flanks of 6-8-week-old female BALB/c mice for 21 
days. MatrigelTM incorporation into injection methods influences uniformity and reproducibility 
of Renca tumour models by maintaining the integrity of cells after subcutaneous injection (Yu et 
al., 2018). Cells were either resuspended in 100L of 1 x PBS alone and/or 1:1 dilution of 1 x 
PBS and Corning (GFR) MatrigelTM Membrane, subcutaneously into the right flanks of 6-8-
week-old female mice, to rule out any effects of MatrigelTM use on tumour development. 
Bilateral injection of Renca tumours allowed us to compare tumour growth between KIM-1pos 
and KIM-1neg tumours in the same host (i.e., same immune system). I did not observe any 
significant differences in tumour volume or mass between KIM-1pos and KIM-1neg tumours both 
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Figure 4. Mass and volumes of KIM-1pos and KIM-1neg Renca tumours grown SQ-Bilat. 
A. KIM-1pos and KIM-1neg Renca tumour volume and mass, grown without MatrigelTM for 21 
days in 6–8-week-old female mice (n=11/group) (volume: NS, p=0.3080, mass: NS, p=0.3251). 
B. KIM-1pos and KIM-1neg Renca tumour volume and mass, grown with MatrigelTM for 21 days 
in 6–8-week-old female mice (n=24/group) (volume: NS, p=0.3673, mass: NS, p=0.4629). Data 
is represented as mean measurement of tumour size/volume (mm3), and mass (g) ± SEM 











3.5 KIM-1 expression in Renca cells does not alter tumorigenic potential when 
injected unilaterally into BALB/c mice. 
 
Next, I investigated whether unilateral injection methods of KIM-1pos or KIM-1neg Renca cells 
into the flanks of BALB/c mice would change the results observed in the previous experiment. I 
argued that if KIM-1 expression in Renca cells had any effect on the anti-tumour immune 
response to Renca tumours, unilateral injection of the KIM-1pos and KIM-1neg cells into separate 
mice would result in differences between the two groups. Once again, I either suspended the 
Renca cells in a 1 x PBS alone or a 1:1 dilution of 1 x PBS with Corning (GFR) MatrigelTM 
Membrane. Again, I did not observe any differences between KIM-1pos and KIM-1neg Renca 
tumour volume or mass in our unilateral model both without MatrigelTM (Fig 5A) or with 
MatrigelTM (Fig 5B). Since I found no differences between SQ-Bilat or SQ-Unilat tumour 
volumes and masses, here on in I decided to analyze tumour specimens only with the 
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Figure 5. Mass and volumes of KIM-1pos and KIM-1neg Renca tumours grown SQ-Unilat. 
A. KIM-1pos and KIM-1neg Renca tumour volume and mass, grown without MatrigelTM for 21 
days in 6–8-week-old female mice (KIM-1neg: n=10, KIM-1pos: n=11) (volume: NS, p=0.9071, 
mass: NS, p=0.1538). B. KIM-1pos or KIM-1neg Renca tumour volume and mass, grown with 
MatrigelTM for 21 days in 6–8-week-old female mice (n=8/group) (volume: NS, p=0.7854, mass: 
NS, p=0.3005). Data is represented as mean measurement of tumour size/volume (mm3), and 












3.6 Tumour KIM-1 expression does not influence immune infiltration of 
lymphocytes in the subcutaneous Renca model. 
 
To investigate the effect of KIM-1 expression on the immune response against Renca tumours, I 
compared the immune infiltrate between KIM-1pos and KIM-1neg Renca tumours grown 
subcutaneously within female immune competent BALB/c mice using co-immunofluorescence 
staining for CD3+, CD3+CD4+, and CD3+ CD8+ cells. We examined tumours at 21 days post-
injection to allow for maximal infiltration of immune cells. There were no significant differences 
in tumour infiltrating CD3+, CD4+, or CD8+ immune cells between Renca KIM-1pos (Fig 6A) and 
KIM-1neg (Fig 6B) tumours (Fig 6C).  
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Figure 6. Co-immunofluorescence staining for CD3+, CD4+ and CD8+ invading lymphocytes in 
KIM-1pos and KIM-1neg Renca tumours 21 days after SQ-Bilat injection. 
A. KIM-1pos and B. KIM-1neg Renca tumour stained with CD3+ (green) CD4+ (blue) CD8+ 
(white) conjugated antibodies (n=4/group). C. Quantification of the various types of immune 
infiltrates counted within tumours. Designated arrows pointing to cell types [CD3+ (green) CD4+ 
(blue) CD8+ (white)] on inlet images. All images were taken via widefield microscopy using 
Leica Software at 10x and 100x magnification, respectively. Immune infiltrates were enumerated 
using Fiji manual cell counter software. Data is represented as mean measurement of number of 
immune infiltrates per tissue surface area ± SEM (CD4+. p= 0.218575, NS; CD8+, p= 0.999170, 








3.7 KIM-1pos Renca tumours are enveloped in a collagen-rich capsule. 
 
Since I elucidated that various collagen genes are significantly upregulated in RCC patient 
tumours, I next examined differences in connective tissues within KIM-1pos and KIM-1neg Renca 
tumours at endpoint (21 d) by staining for collagen using Masson's Trichrome stain. KIM-1pos 
tumours were found to be surrounded by a significantly thicker collagen dense capsule compared 
to the KIM-1neg tumours (Fig 7A-C). Importantly, the collagen dense capsule was found to be 
prominent in Renca KIM-1pos regardless of whether the Renca cells were injected bilaterally into 
either flank of the same BALB/c mice or unilaterally into independent mice (MatrigelTM) (Fig 
8A-C). 
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Figure 7. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours injected SQ-Bilat in 
female BALB/c (WT) mice. 
 
Micrograph of A. KIM-1pos and B. KIM-1neg Renca tumour stained with Masson’s Trichrome 
elucidating the collagen stromal capsule (KIM-1neg: n=7, KIM-1pos: n=4). All images were taken 
at 100x magnification using brightfield microscopy and NIS-Elements Nikon software. C. Width 
(μm) quantification of collagen tumour capsule from KIM-1neg and KIM-1pos Renca tumours. 
Data is represented as mean measurement of tumour capsule width (μm) ± SEM (****, 
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Figure 8. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours grown SQ-Uni in 
female BALB/c mice. 
Micrograph of A. KIM-1pos and B. KIM-1neg Renca tumours stained with Masson’s Trichrome 
elucidating the collagen stromal capsule (KIM-1neg: n=7, KIM-1pos: n=8). All images were taken 
using brightfield microscopy and NIS-Elements Nikon software. C. Width (μm) quantification of 
collagen tumour capsule from KIM-1neg and KIM-1pos Renca tumours. Data is represented as 





3.8 The collagen-dense capsule surrounding KIM-1pos Renca tumours does not 
depend on the host adaptive immune system. 
 
To determine whether the differences in collagen dense capsule surrounding the Renca 
KIM-1pos tumours was dependent on an intact adaptive immune system of the host, I examined 
KIM-1pos and KIM-1neg Renca tumours growth in immune deficient Rag-1-/- mice on the BALB/c 
background. Once again, the tumours were collected 21 days post-injection and sections were 
stained with Masson’s Trichrome stain. KIM-1pos Renca tumours exhibited significantly thicker 
collagen dense capsules in comparison to KIM-1neg Renca tumours (Fig 9A-C). 
A.                 B.  















Figure 9. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours grown SQ-Bilat in 
Rag1 -/- mice. 
Micrograph of A. KIM-1pos and B. KIM-1neg Renca tumour stained with Masson’s Trichrome 
elucidating the collagen stromal capsule (n=5/group). All images were taken at 100x 
magnification using brightfield microscopy and NIS-Elements Nikon software. C. Width (μm) 
quantification of collagen tumour capsule from KIM-1pos and KIM-1neg Renca tumours. Data is 
represented as mean measurement of tumour capsule width (μm) ± SEM (*, p = 0.0120, 
Unpaired two-tailed t-test). 
 
 
3. 8 KIM-1 expression inhibits Renca tumour growth in an orthotopic model 
of RCC.  
 
RCC tumours arise from the proximal tubule of the kidney and can metastasize to distant sites 
such as the lung. To test the role of KIM-1 on tumour growth within the kidney and on 
metastasis to the lungs, I orthotopically injected KIM-1pos or KIM-1neg Renca cells into the renal 
subcapsular space of BALB/c mice. Previous studies have claimed that Renca cells are able to 
grow in the kidney and preferentially metastasize to the lungs within 2 weeks of intra-renal 
injection (Feldman et al., 2016). Renca cells were injected with MatrigelTM into the subcapsular 
region of the left kidney. The volume and weights of the KIM-1pos Renca tumours were 







cells also had fewer metastatic lung nodules compared to mice injected with KIM-1neg Renca 
cells, albeit this was not significant (Fig 13A-C).  
 
   
     
Figure 10. Volumes and weights of KIM-1pos and KIM-1neg Renca tumour after orthotopic 
injection into BALB/c mice. 
Tumour bearing kidney volume and mass respectively, 21 days post orthotopic injections of 
KIM-1pos or KIM-1neg Renca cells (n=15/group). Data is represented as mean measurement of 
tumour size/volume (mm3), and mass (g) ± SEM (volume, **, p = 0.0024; mass, **, p = 0.0045, 
Unpaired two-tailed t-test).  
 
3. 9 KIM-1pos Renca tumours do not produce a collagen rich capsule when 
injected orthotopically into BALB/c mice. 
 
To investigate if orthotopic injection of KIM-1pos Renca cells produce tumours with a 
collagen rich capsule, both KIM-1pos and KIM-1neg Renca tumours grown orthotopically in 
female BALB/c mice were subjected to Masson's Trichrome staining. Analysis of kidney bearing 
tumours revealed no measurable differences in capsule size between both KIM-1pos and KIM-1neg 
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Figure 11. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours grown orthotopically 
in BALB/c mice. 
Micrograph of A. KIM-1pos and B. KIM-1neg kidney bearing Renca tumours stained with 
Masson’s Trichrome elucidating the lack of collagen stromal capsule. All images were taken at 
100x magnification using brightfield microscopy and NIS-Elements Nikon software. 
 
 
3.10 Tumour KIM-1 expression does not influence immune infiltration of 
invading lymphocytes in the orthotopic Renca model. 
 
Next, I investigated whether KIM-1 expression on Renca tumours had any effects on 
tumour infiltrating T cells in our orthotopic model.  KIM-1pos and KIM-1neg tumour-bearing 
kidneys were stained for CD3+, CD3+CD4+, and CD3+ CD8+. We examined tumours at 21 days 
post-injection to allow for maximal infiltration by immune cells. There were no significant 
differences in tumour infiltrating CD3+, CD4+, or CD8+ T cells between Renca KIM-1pos and 
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Figure 12. Co-immunofluorescence staining for CD3+, CD4+, and CD8+ invading lymphocytes 
in KIM-1pos and KIM-1neg Renca orthotopic tumours from BALB/c mice after 21 days. 
Micrographs of A. KIM-1pos and B. KIM-1neg Renca tumour stained for CD3+ (green) CD4+ 
(blue) CD8+ (white) (KIM-1pos: n=3, KIM-1neg: n = 2). C. Quantification of the various types of 
immune infiltrates counted within tumours. Designated arrows pointing to cell types [CD3+ 
(green) CD4+ (blue) CD8+ (white)] on inlet images. All images were taken via widefield 
microscopy using Leica Software at 10x and 100x magnification, respectively. Immune 
infiltrates were enumerated using Fiji manual cell counter software.  
 
 
3. 11 KIM-1 expression does not affect spontaneous metastasis from the 
kidneys to lungs in the orthotopic model of RCC. 
 
We next investigated whether KIM-1 expression had any impact on the process of 
metastasis from the kidney to the lungs by collecting the lungs at day 21 and examining them for 
metastatic nodules using microscopy.  Histological examination of the lung tissues revealed no 
statistically significant differences in the number of metastatic nodules, as well as no differences 
in collagen encapsulation between mice injected orthotopically with KIM-1pos or KIM-1neg Renca 
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Figure 13. Number of metastatic lung nodules in BALB/c mice injected orthotopically with 
KIM-1pos or KIM-1neg Renca cells. 
Micrographs of H&E-stained sections of lung tissue excised from A. KIM-1pos and B. KIM-1neg 
Renca cell treated mice (n=8/group). C. Quantification of metastatic lung nodules formed within 
both KIM-1pos and KIM-1neg Renca cell treated mice. Nodules were enumerated by manually 
counting visualized metastases. Metastases are indicated using arrows. All images were taken 
using brightfield microscopy and NIS-Elements Nikon software. Data is represented as mean 
measurement of number of metastatic nodules per tissue surface area ± SEM (NS, p = 0.2073, 











3.12 KIM-1 expression in Renca cells promotes transcription of genes involved 
in the formation and interaction with extracellular matrix.  
 
To understand how KIM-1 expression promotes the formation of collagen rich capsules by  
Renca tumours, I analyzed our previously generated RNA sequencing data from both KIM-1pos 
and KIM-1neg Renca cells (Lee and Gunaratnam, 2019). The most significant gene enrichment 
that was upregulated within the Renca KIM-1pos cells was in genes involved in Extracellular 
Matrix Interaction (p < 0.05, fold change 1.96) (Fig 14A and B). This enrichment contained 
genes involved in the interaction and deposition of extracellular matrix (ECM). Moreover, the 
most significantly upregulated collagen genes within KIM-1pos Renca cells was COL6A1 and 
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Figure 14. Illumina RNA-Sequencing transcriptomic analysis of enriched Extracellular Matrix 
Genes between KIM-1pos and KIM-1neg Renca cell lines. 
A. Heat map generated from RNA Sequencing data of KIM-1pos and KIM-1neg Renca cell lines 
(n=3/group), displaying differential gene enrichment analysis of extracellular matrix (ECM) 
genes (p>/=0.05). Genes with increased numbers of transcripts are marked as red, while 
decreased are marked as green. B. List of ECM genes that have significant increased expression 
in KIM-1pos Renca cells, in comparison to KIM-1neg Renca cells. C. Collagen 6 A 1 and Collagen 




Table 1. Mouse Oligonucleotide PCR primer sequences 
 
Primer Sequence (5’  3’) 








































4.1 Major Findings 
4.1.1 KIM-1 (Havcr1) mRNA is expressed at all stages of RCC and increases 
overall patient survival 
 
Multiple studies have identified KIM-1 as a urine or blood biomarker for the early 
detection of RCC (Scelo et al., 2018).  This was made possible through sensitive detection of 
shed or soluble KIM-1 (sKIM-1) in the blood plasma and urine (Scelo et al., 2018) of RCC 
patients. Our laboratory previously showed that cell-surface KIM-1 is shed by ADAM17 or 
TACE in RCC cells (Gandhi et al., 2014). Using the TCGA KIPAN database, specifically 
analyzing KIRC (Kidney Clear Cell Carcinoma) and KIRP (Kidney Papillary Carcinoma) patient 
databases, I was able to show that increased KIM-1 mRNA is highly upregulated in human RCC 
patients (Fig 1). KIM-1 expression was found to be significantly increased as early as stage I 
disease, with persistent expression through stages I-IV. Given that KIM-1 is only upregulated 
during acute kidney injury (AKI) (Han et al., 2005), and the early detection of KIM-1 in the 
blood of RCC patients (Scelo et al., 2018), these data confirm that KIM-1 is likely upregulated in 
early RCC lesions (Han et al., 2002). The reason for this upregulation is unclear, but it is not due 
to VHL-loss of function (unpublished observations).  In addition, higher KIM-1 expression was 
associated with significantly increased overall survival rates in KIRC (ccRCC) patients, yet not 
KIRP (papillary RCC) patients (Fig 1C, D and E). These data are in contradiction to findings 
reported by Scelo and team (Scelo et al., 2018), that high plasma KIM-1 concentrations were 
associated with poorer survival. Our study, however, examined endogenous tumour KIM-1and 







Many groups, including Dr. Gunaratnam’s,  have shown that during AKI, KIM-1 converts 
proximal tubular epithelial cells (PTECs) into semiprofessional phagocytes for clearance of 
apoptotic and necrotic cells of (Arai et al., 2016). KIM-1 recognizes and binds to 
phosphatidylserine (PtdSer) – a phospholipid abundantly expressed on early necrotic and 
apoptotic cells – via the metal ion-dependent ligand binding site within its IgV domain (Nagata 
et al., 2016). The clearance of dying cells leads to curtailment of inflammation and promotes 
tissue repair. The function of KIM-1 in RCC may be linked to its reparative role in the healthy 
kidney during acute injury, where an increase in KIM-1 expression reduces the amount of 
apoptotic or early necrotic cells formed in tumours, thereby significantly reducing tumour burden 
and promoting cell regeneration and repair (O. Z. Ismail et al., 2016). This in turn could explain 
why patients with higher levels of KIM-1 expression, exhibit more favorable outcomes.  
4.1.2 ECM signatures are upregulated in human RCC  
 
Previous studies have underscored the importance of tumour stroma and ECM components in 
tumour progression and metastasis (Yuzhalin et al., 2018). RCC is known to upregulate adhesion 
molecules (Chen et al., 2016), moreover, several collagen genes exhibiting increased mRNA 
expression have been found in human RCC tumours and linked to tumour grade (Best et al., 
2019). Collagen genes such as Collagen 1 (COL1) (Majo et al., 2020), Collagen 6 (COL6) (Wan 
et al., 2015), and Collagen 23A1 (COL23A1) (Xu et al., 2017) have been shown to be 
upregulated in RCC tumours. Collagen in cancer has been found to be both beneficial and 
detrimental to patients in terms of tumour progression (Fang et al., 2014), although the 
mechanistic role of collagen in RCC is not well understood. Furthermore, chronic KIM-1 
expression after AKI has been linked to kidney fibrosis in vivo (Humphreys et al., 2013). Our 







(i.e. COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1) were all significantly upregulated in 
RCC tumour tissues vs adjacent normal tissues (Fig 2). A recent study found that Col6a1 
promotes metastasis and a poorer prognosis in pancreatic cancer patients (Owusu-Ansah et al., 
2019). Another study found Col23A1 is upregulated in RCC, and contributes to tumour 
progression (Xu et al., 2017). On the other hand, down-regulation of Col1A2 by methylation  
was found in both bladder (Mori et al., 2009), and melanoma cancer (Bonazzi et al., 2011). The 
role of these various collagen genes across multiple types of cancer remains controversial. When 
correlating KIM-1 expression to the TMI signature gene list (Lim et al., 2019), along with 
previous collagen genes of interest (COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1), I 
found no clear correlation trends between these collagen signatures and KIM-1 expression in 
RCC patients (Fig 3). Although, when comparing KIM-1 expression to COL1A2, COL6A1, 
COL6A2, and COL23A1 - these were found to positively correlate to KIM-1 expression in RCC. 
Many of the genes within the TMI signature (Lim et al., 2019) had either a significant positive or 
negative correlation to tumour KIM-1 mRNA – although further investigation behind the specific 
genes must be completed before additional conclusions can be made. Previous research has 
shown that during AKI, KIM-1 expression is beneficial in early acute stages of injury but chronic 
expression of KIM-1 promotes renal fibrosis (Humphreys et al., 2013). Cell types implicated in 
the process of fibrosis are fibroblasts and myofibroblasts that aid in tissue remodeling and the 
secretion of extracellular matrix components such as collagen (Wynn, 2008). The positive 
correlation of collagen genes in KIM-1 expressing Renca cells may be a protective mechanism 
by the kidney. It may be possible that KIM-1 expression in renal malignancies causes similar 
effects. This would suggest that chronic KIM-1 expression leading to fibrosis, may be a 







exact interaction – if present – between KIM-1 and COL1A2, COL6A1, COL6A2, and COL23A1 
needs to be confirmed through more mechanistic studies.  
 
4.1.3 KIM-1 does not alter tumour growth in an immune competent 
subcutaneous Renca model  
 
Multiple studies have identified the subcutaneous model as a stable murine model to study RCC 
tumour biology (Sobczuk et al., 2020). Using the bilateral and unilateral subcutaneous models, I 
compared the growth of KIM-1pos and KIM-1neg Renca tumours in immune competent mice. The 
bilateral model is an ideal model to use as it minimizes the genetic heterogeneity between 
individual mice that could cause variations in response to the same treatment. Bilateral models 
are better suited to studying the effect of tumours on the host immune system (e.g. immune 
check-point blockade) (Zemek et al., 2020). I found that KIM-1 had no effect on tumour growth 
regardless of whether we used the bilateral or unilateral approach (Fig 4 and 5). Previous studies 
have found that Renca tumour growth in vivo had inconsistent tumour growth kinetics in the 
absence of MatrigelTM (Yu et al., 2018). Following this study, I revised my protocol to 
CDTRresuspend our Renca cells in growth factor reduced MatrigelTM prior to both bilateral and 
unilateral subcutaneous injection. My studies produced consistent tumour sizes and masses with 
smaller standard deviations. Therefore, I am confident of my findings showing that KIM-1 
expression does not alter the tumour size or mass produced by Renca cells implanted 








4.1.4 KIM-1 expression promotes the formation of a collagen dense capsule 
around Renca tumours injected subcutaneously into both immune competent 
and immune deficient mice  
 
Dysregulated collagen production has been linked to a more malignant phenotype in various 
cancers (Seager et al., 2017). On the other hand, many benign tumours are known to be 
surrounded by a capsule consisting of connective tissue. My findings suggest that KIM-1 
expression promotes transcription of various collagen genes in human RCC tumours and 
formation of a collagen-rich capsule surrounding the Renca tumours. Interestingly, I observed 
the formation of the capsule around KIM-1pos Renca tumours only when injected subcutaneously 
but not orthotopically (Fig 7, 8 9, and 11). The use of MatrigelTM did not affect these results. 
Some studies have suggested that the collagen rich tumour capsule directly interacts with the 
host immune system, and thus, the ensuing interaction strongly impacts tumour progression 
(Seager et al., 2017). Given that the tumour capsule was present on KIM-1pos Renca tumours 
grown in wild type BALB/c and RAG1-/- BALB/c mice,  my data suggests that the formation of 
the capsule does not depend on the interaction of tumour cells and the adaptive immune system, 
yet is dependent on the site of injection (subcutaneous vs orthotopic). Specifically, we can 
assume that the collagen capsule is localized to the tumour stroma due to the interaction between 
tumour-associated KIM-1 and the surrounding cells of the subcutaneous microenvironment. 
Given that there were no differences in volume or mass between the subcutaneous KIM-1pos and 
KIM-1neg Renca tumours regardless of host immune status (WT BALB/c or Rag1-/- BALB/c 
mice), it could be argued that the capsule does not alter the T- or B cells responses against the 









4.1.5 KIM-1 expression does not alter frequency or distribution of invading 
lymphocytes in both subcutaneous and orthotopic Renca models 
 
The tumour microenvironment plays a key role in anti-tumour immunity (Applegate, Balch and 
Pellis, 1990). Intra- and extra-tumoral cell signaling, tumour and cell metabolism, and 
oxygenation are all factors that influence tumour progression and metastasis - can be determined 
by the surrounding tumour microenvironment (Henke, Nandigama and Ergün, 2020). Tumour 
microenvironment components can differ significantly between tumour types, but the main 
components are invading or surrounding immune cells, the vasculature, stromal cells and the 
tumour associated ECM (Anderson and Simon, 2020). In most cases, the tumour cells seem to 
orchestrate the surrounding cells to promote a microenvironment favorable for growth and/or 
metastasis (Walker, Mojares and Del Río Hernández, 2018). It is well known that tumour 
associated ECM (including collagen) is able to inhibit the invasion of immune cells into the 
tumour parenchyma and/or alter the phenotype of the invading immune cells to promote cancer 
progression (Maller et al., 2020). Also, depending on the density of tumour associated collagen, 
the ECM can inhibit the positioning and migration of T cells, resulting in possible T cell 
exclusion from the tumour periphery (Kuczek et al., 2019). Increased tumoral collagen has also 
been found to exhaust CD8+ T cells through direct contact with T cell markers, LAIR1 (Peng et 
al., 2020). This phenomenon has been observed in many cancers such as triple-negative breast 
cancer, pancreatic cancers (Kuczek et al., 2019) and lung cancer (Salmon et al., 2012). 
Organization and location of tumour associated ECM structures are commonly positioned around 
vasculature structures or the stromal interface. Specifically, research has shown that both 
perivascular and loose organized structures of the ECM in particular are where most of the intra-







Renca tumours develop significantly thicker collagen dense stromal capsules. Yet, I observed no 
significant differences in the distribution or frequencies of invading lymphocytes within 
subcutaneous KIM-1pos or KIM-1neg Renca tumours (Fig 6). CD4+ and CD8+ T cells were chosen 
for analysis due to the compelling research that: 1) T cells are fundamental to anti-tumour 
immunity; 2) known exclusion or inhibitory mechanisms via collagen deposition targets both T 
cell subsets.  
 
We have no concrete conclusions about the distribution or frequency of invading lymphocytes 
within KIM-1pos and KIM-1neg Renca tumours grown orthotopically (Fig 12). Due to the small 
sample size of my KIM-1neg group, additional experiments will be required to confirm whether or 
not there are any real differences. Further characterization of the immune infiltrate and 
evaluation of the effector function of invading lymphocytes in KIM-1pos vs. KIM-1neg Renca 
tumours, may help elucidate the mechanism responsible for inhibiting tumour growth in our 
orthotopic model.  
4.1.6 KIM-1 expression inhibits tumour growth in an orthotopic Renca model  
Subcutaneous tumour models are widely used for in vivo cancer studies and allows for growth of 
the tumour below the skin to become a highly vascularized area. This allows for rapid tumour 
growth that is easily monitorable using calipers, permitting a rapid assessment of growth kinetics 
overtime (Zhang et al., 2019). There are several limitations to the subcutaneous tumour model in 
comparison to other experimental cancer mouse models. Subcutaneous tumour models allow for 
the simple monitoring of biological staging yet are is not feasible for studying metastasis (Zhang 
et al., 2019) – as it is not often observed in subcutaneous models (Gomez-Cuadrado et al., 2017). 







not reflect the development of human cancers in native tissues (Zhang et al., 2019). Therefore, 
orthotopic mouse models are regarded as a more clinically relevant model for the study of human 
cancers including progression, metastasis and therapeutic intervention. Orthotopic models have 
been shown to better correspond to human cancer development in terms of histology, tumour 
vasculature, response to therapies/treatments, and of course the metastatic cascade to nearby and 
distant organs (Khanna and Hunter, 2005). A recent study evaluating BB3r-targeted therapy in 
both subcutaneous vs orthotopic mouse models of prostate cancer, found that orthotopic models 
had overall higher tumour uptake, increased vascular perfusion, and lower burden of hypoxia. 
Overall findings from this study concluded that the tumour microenvironmental differences 
between subcutaneous and orthotopic models differs greatly (Zhang et al., 2019). Another study 
recently compared the interactome profiles of gastric cancer – OE19 adenocarcinoma - using 
both subcutaneous and orthotopic xenograft models. Pathway analysis using RNA sequencing 
revealed various significantly enhanced pathways within orthotopic models in comparison to 
subcutaneous models.  More vascular invasion were found within orthotopic models - observing 
increased interactions between cancer and stromal cells – with orthotopic models thought to have 
higher interplay with the surrounding microenvironment (Nakano et al., 2018). Prior to our 
research, the discrepancies between subcutaneous vs orthotopic models in RCC was unknown. 
Overall, I am the first to uncover the major differences between subcutaneous and orthotopic 
mouse Renca tumour models and how they dictate the interaction between cancer cells and 
surrounding stromal cells. My results found that KIM-1pos Renca cells create significantly 
smaller primary tumours in - comparison to KIM-1neg Renca cells - when injected orthotopically 
into the subcapsular space of the kidney, but not subcutaneously, in immune competent mice 







in RCC (Lee and Gunaratnam, 2019), as patients with higher levels of KIM-1 expression resulted 
in an increased overall survival rate (Fig 1C). However, my findings also differ from that of 
(Cuadros et al., 2013), who  proposed that KIM-1 promotes tumour progression. In contrast to 
these studies, my findings suggest KIM-1 does not promote tumour progression, and in fact, 
inhibits tumour growth in my orthotopic studies.   
One study investigated the differences in membrane bound tissue KIM-1 as well as soluble 
cleaved KIM-1, in regard to their differential effects on RCC progression. Microvascular 
invasion – the invasion of cancer cells into the endothelium of blood vessels – was correlated 
with increased tissue KIM-1 expression in clear cell RCC (ccRCC) tumours. This study also 
found that increased levels of soluble KIM-1 detected in the urine correlated with increased 
TNM staging and overall exacerbated disease progression (Mijuskovic et al., 2018). Another 
study stated that when analyzing RCC patient plasma, higher concentrations of soluble KIM-1 
were associated with poorer survival rates (Scelo et al., 2018). On the other hand, the 
Gunaratnam laboratory has shown that KIM-1 expression on TECs is able to inhibit Gα12, 
subsequently inhibiting a small GTPase RhoA, which is found to increase metastatic progression 
of cancers (Z. O. Ismail et al., 2016). Although the mechanistic correlation between KIM-1 and 
Gα12 expression in RCC in vitro/in vivo work was not further investigated. Despite these 
findings, the clear role of KIM-1 expression in the pathogenesis and progression of RCC remains 
not well understood.  The discrepancy between my study and those discussed above may be 
explained by my studies involving multiple in vivo systems (subcutaneous vs orthotopic), and 







4.1.7 KIM-1 does not promote collagen capsule formation in an orthotopic 
Renca model  
 
As mentioned above, previous studies have shown that orthotopic tumour models better mimic 
the natural biology of tumour progression (Nakano et al., 2018). Surprisingly, my data showed 
no significant differences between KIM-1pos and KIM-1neg collagen capsules in our orthotopic 
model (Fig 11), yet in our subcutaneous model, KIM-1pos Renca tumours bared significantly 
thicker collagen dense capsules in both immune competent and deficient mice. This discrepancy 
may be explained by differences in the (tumour) surrounding cells (skin vs. kidney) which the 
Renca cells recruit to form the microenvironment. Conceivably, the skin may be a more 
permissive environment for the formation of a collagen rich matrix (Cox and Erler, 2011).  One 
study found that the adipose tissue of rats located within the subcutaneous space, strongly varied 
from visceral adipose tissue. This study observed subcutaneous adipose gene clusters strongly 
relating to ECM related genes involving collagen, cell adhesion, and proteases. Expression 
profiles revealed major fibril-forming collagen genes that were upregulated were Collagen I, 
Collagen III, Collagen V, and Collagen VI, along with the more common ECM related genes 
such as Lama, Fibronectin 1, and Collagen IV (Mori et al., 2014). Although this study was 
performed in rats, previous research on adipose tissue has suggested that both mice and rats are 
comparable to one another (National Human Genome Research Institute, 2004). Another study 
found that when comparing ECM of subcutaneous tumours and in vitro tumour spheroids (a 
three-dimensional cell culture model), the subcutaneous tumours had an increased collagen 
content (De L Davies et al., 2002) likely due to the proximity to cells within the adjacent 







may give reason as to why we observed a significantly thicker collagen capsule formation in 
KIM-1pos Renca tumours within our subcutaneous, but not orthotopic model.   
4.1.8 KIM-1 does affect spontaneous metastasis of Renca cells to the lungs in 
an orthotopic model 
 
Late stage RCC (III-IV) involves tumour growth into the renal vein, inferior vena cava, or to 
regional lymph nodes, each of which must pass the Gerota’s fascia – the fibrous envelope 
encapsulating the kidney. Common sites of metastasis in RCC include the lungs, adrenal glands, 
and bones – whilst the lungs being the most common site of metastasis, found in up to 50%-60% 
of autopsies (Reznek, 2004). Orthotopic injection of Renca cells are widely used as a model to 
study the metastatic cascade of RCC (Hillman, Droz and Haas, 1994; Gomez-Cuadrado et al., 
2017). Although our orthotopic experiments revealed that the KIM-1pos Renca tumours were 
considerably smaller than the KIM-1neg Renca tumours, the small sample size precluded 
determining whether there were significant differences in the metastatic potential to the lungs 
between the KIM-1pos or KIM-1neg Renca cells (Fig 13). My data showed significantly fewer 
metastatic nodules compared to other studies employing Renca cells (Feldman et al., 2016) 
where metastatic nodules compromised ~70% of lung tissue, whereas in my study both KIM-1pos 
and KIM-1neg Renca treated mice had only ~15 metastatic nodules observed per mouse. 
Secondary metastatic nodules also presented no differences in collagen encapsulation between 
groups. There are multiple potential explanations as to why I observed less metastasis in my 
experiments. I followed the protocol from Feldman Ret al., injecting 2 x 105 KIM-1pos or KIM-
1neg Renca cells into the subcapsular space of the left kidney. This study used an endpoint for the 
assessment of metastases at 14 days post-injection and this resulted in sufficient primary tumour 







(Feldman et al., 2016). Another study by Murphy et al., injected Renca cells directly into the 
kidney – intrarenal implantation – to study metastatic RCC for the assessment of preclinical 
therapies (Murphy et al., 2017). At 23 days after injection of Renca cells into the renal 
cortex/medulla, using BLI to assess tumour burden, this study observed significantly more 
metastasis than I did with subcapsular injection. Potential explanations for the low numbers of 
metastatic nodules in my model could be: 1) Subcapsular vs. intra-renal injection of Renca cells; 
2) improper injection and leakage of cells outside the kidney; 3) reduced malignancy of our 
Renca cell lines upon transduction with Lentivirus. The use of luciferase expressing Renca cells 
may allow for more sensitive detection of metastatic foci when using real -time bioluminescent 
imaging (BLI).  
4.1.9 KIM-1 expression increases transcription of ECM related genes in 
Renca cells  
 
My data from the subcutaneous model of RCC revealed that KIM-1pos Renca tumours obtain a 
significantly thicker collagen dense stromal capsule in comparison to KIM-1neg Renca tumours, 
independent of adaptive immunity. Surprisingly, my orthotopic model of RCC revealed no 
significant differences in collagen stromal capsule formation between my tumour groups. In 
efforts to elucidate how KIM-1 expression may alter mechanistic pathways allowing for ECM 
production in our subcutaneous model, I interrogated the transcriptomic profile of KIM-1pos and 
KIM-1neg Renca cells using RNA sequencing and bioinformatic approaches. My data did not 
show many significant differences between our cell lines in terms of pathway analyses, yet we 
did detect a significant gene enrichment of genes involved in Extracellular Matrix Interactions 
(Fig 14). Many of the genes involved in this enrichment, are involved in extracellular matrix 







a transcription factor which regulates multiple extracellular matrix related genes. I believe these 
findings correlate to the clinically relevant findings from TCGA between KIM-1 and collagen. 
Interestingly, two significantly upregulated genes that were found in the RNA Sequencing of the 
Renca cell lines – COL6A1, COL6A2 – are also found in my TCGA data where these collagens 
are significantly upregulated in RCC patient and positively correlate with KIM-1 expression. 
These findings further validate our KIM-1 overexpression Renca model, revealing the 
similarities between our Renca cell lines and RCC patient transcriptomic profiles.  
4. 2 Limitations  
4.2.1 Subcutaneous Mouse Model 
 
Although subcutaneous models are widely used in oncological research, there are major 
drawbacks of this method. Initially I had difficulties in trying to overcome the variability in 
tumour volume and weight differences between our KIM-1pos and KIM-1neg groups. As stated 
previously, there are many drawbacks of the model, most of which surround the 
microenvironment, and clinical relevance. Studies have found that subcutaneous models 
although non-invasive, the microenvironment implantation causes the tumour to behave as a 
benign tumour rather than malignant tumour, owing to the reduced propensity to form metastases 
(Sordat, 2017). One study found significant inconsistencies in tumour formation due to the vast 
variations in angiogenesis and tumour vasculature within the subcutaneous pocket where 
injections occur (Lwin, Hoffman and Bouvet, 2018). These studies could explain why we had 
difficulties obtaining consistent results with our subcutaneous model. Another study - 
investigating various tumour immune profiles of murine syngeneic tumour models - found that 







factor reduced basement membrane MatrigelTM, in order to facilitate consistent growth patterns 
(Yu et al., 2018). Following this protocol, I repeated my subcutaneous injections of 1 x 106 KIM-
1pos and KIM-1neg Renca cells this time in a 1:1 dilution of 1x PBS and growth factor reduced 
MatrigelTM. With this addition to my subcutaneous injection model, I was able to find data with 
tighter standard deviations in my tumour volumes and masses in both KIM-1pos and KIM-1neg 
tumour results. Although there was visibly less variability, incorporation of MatrigelTM did not 
cause uniformity in shape, resulting in abnormally shaped subcutaneous tumour growth still 
remaining an issue. These facts, coupled with my results, underscore the limitations of this 
model that are likely related to the microenvironment of the murine subcutaneous tissue.  
4.2.2 Orthotopic Experimental Model 
 
Although extremely useful and clinically relevant given the clinical cascade of human RCC, the 
orthotopic kidney tumour model is widely dependent on technique (Bibby, 2004). Subcapsular 
injections into the kidney are extremely difficult and can easily cause high variability between 
injections. A major drawback of orthotopic implantation is the high likelihood of leakage of the 
inoculate outside the kidney (Sasaki et al., 2015). Although my surgeries were performed by an 
experienced veterinary surgeon and implemented with the use of growth factor reduced 
MatrigelTM in order to minimize leaking, this process can still occur late after surgery, and in 
some cases are unavoidable. Overall, the orthotopic model remains the most clinically relevant 
one despite its technical limitations. 
4.2.3 Renca Cell Line 
 
Renca cells are perhaps the most commonly used murine cell lines for in vivo RCC studies. They 







making the cell line syngeneic when injected into BALB/c mice. Renca cell lines are known to 
not fully reflect the genetics of human RCC, although they importantly possess the VHL (Von 
Lippen Lindau) deletion – causing epithelial mesenchymal transition (EMT) and HIF-1 α 
stabilization – which accurately represent the biology of human RCC tumours (Wolf, Kimryn 
Rathmell and Beckermann, 2020). Despite the overall concrete research that supports the use of 
Renca cell lines, I experienced several problems with our subcutaneous models (as stated above) 
that could be due to our cell line of choice. Yu  et al. studied the tumour immune profiles of 
Renca tumours in different syngeneic mouse models and found Renca cells to be highly 
immunogenic - able to elicit an adaptive immune response (Yu et al., 2018). Renca tumours are 
known to be highly infiltrated by immune cells from both the myeloid and lymphoid lineages 
(Wolf, Kimryn Rathmell and Beckermann, 2020). Interestingly, they found that the tumour 
immune profile depended on the size of the tumours in vivo. Through RNA sequencing, they 
found that smaller tumours (~100mm3) had more immune cell infiltrates (including T cells, 
macrophages, and NK Cells), while larger tumours (~500mm3 – 2000mm3) contained more 
myeloid derived suppressor cells (MDSC) expressing NOS2/iNOS, and VEGFA. These 
transcriptomic changes have an impact on immunosuppression, decreased T cell numbers, and 
tumour vasculature. The researchers also stated that Renca cells had to be injected with growth 
factor reduced MatrigelTM to obtain consistent and uniform tumours. Taken together with my 
data, this suggests that tumour size may be predictive of their immune profiles. Yet, this can pose 










4.3 Future Directions and Significance  
4.3.1 Significance  
 
Overall, our findings are somewhat contradictory to previous reports regarding the role of KIM-1 
in RCC. Although, preceding research has evidence to support both theories where KIM-1 can 
either be playing a protective role to patients or a harmful role by contribution to tumorigenicity. 
Some studies suggest that KIM-1 has oncogenic potential and is able to increase the invasiveness 
and progression of RCC tumours (Cuadros et al., 2013). However, clinical data from TCGA 
database demonstrates that higher levels KIM-1 (Havcr1) mRNA in RCC patients is associated 
with greater overall patient survival (Fig 1C). Many in vivo studies investigating the 
pathophysiology of RCC used the subcutaneous murine model,  due to ease of measuring the 
tumours and simplicity. The orthotopic model of RCC is a more clinically relevant model that 
mimics the natural environment (kidneys) of the tumours and their propensity to metastasize to 
the lungs. We have shown variance between Renca tumour phenotypes with respect to both 
growth kinetics and histological differences in our subcutaneous vs. orthotopic models, 
respectively. Despite previous research suggesting that orthotopic models allow for a greater 
cancer-stromal interaction (Nakano et al., 2018), my data suggests that the microenvironmental 
niche of subcutaneous injections allow for an increased production of collagen rich matrix. 
Furthermore, my research demonstrates that increased KIM-1 expression positively correlates 
with increased COL6A1 and COL6A2 mRNA expression in both clinical human RCC (TCGA) 
data, and our Renca murine cell line. In contradiction of the prevailing view that KIM-1 
promotes a more malignant phenotype of RCC, we have showed that KIM-1 expression inhibits 
orthotopic tumour growth in immune competent mice. This thesis work highlights the 







Clinical TCGA data coupled with our data also indicates KIM-1 can possibly inhibit primary 
tumour growth within pre-clinical murine models of RCC.  
4.3.2 Future Directions  
 
The next phase of this project will focus on optimizing my pre-clinical orthotopic model. Results 
from my orthotopic - renal subcapsular RCC model – found significantly fewer lung metastatic 
nodules than expected within both KIM-1pos and KIM-1neg Renca cell injected mice. Optimizing 
this protocol will allow the proper analyses of whether KIM-1 is able to inhibit the process of 
spontaneous metastasis to the lungs in a clinically relevant model of RCC. Next, by subjecting 
KIM-1pos and KIM-1neg orthotopic Renca tumours to RNA sequencing, an analysis of identified 
genetic alterations could then be linked to KIM-1’s ability to inhibit primary tumour growth. My 
previous RNA sequencing showed that KIM-1pos Renca cells have significantly upregulated 
enriched genes involved in ECM receptor interaction. This cellular phenotype directly correlated 
to KIM-1pos subcutaneous Renca tumours obtaining significantly thicker collagen dense stromal 
capsules independent of adaptive immunity. RNA sequencing on KIM-1pos and KIM-1neg 
orthotopic Renca tumours, will also help to elucidate any genetic drivers that could be altering 
the TME, allowing for the phenotypic differences that I have observed in vivo. Lastly, in my 
orthotopic Renca tumour models, I have been able to observe a trending towards significance in 
the frequency of CD3+ immune cells – where KIM-1pos contains more in comparison to KIM-1neg 
Renca tumours. Although I analyzed the frequency and distribution of CD3+, CD3+CD4+, and 
CD3+CD8+ immune cells, I did not evaluate their effector function. Analysis of orthotopic Renca 
tumours using flow cytometry to investigate the presence of immunomodulatory cytokines such 
as IFNγ and IL-2, could give rise to the functionality of the immune cells present. This analysis 







Renca tumours. These findings can also be elucidated by performing co-immunofluorescence 
staining for more specific immune markers such as T-cell exhaustion markers such CD44 or 
LY6C, to evaluate the activator state of T lymphocytes present.  
 
Once the orthotopic Renca model is optimized, it will be possible to test the effect of an agonist 
anti-KIM-1 antibody (RMT1-10) on the growth, dissemination and development of primary 
tumours and metastatic nodules within the orthotopic model (Ichimura, Brooks and Bonventre, 
2012). This may determine whether KIM-1’s seemingly inhibitory effect on primary and 
secondary tumour growth can be enhanced with RMT1-10 delivery. When treating RMT1-10, 
we would expect to see stimulation of KIM-1 which may enhance its anti-tumour growth effects 
in RCC cells previously observed by our group  (Lee et al., 2021). 
4.4 Conclusion  
 
My research has revealed novel insights into the role of KIM-1 in RCC. Moreover, it has 
highlighted the significant differences between subcutaneous and orthotopic models used for pre-
clinical oncological studies. The expression of KIM-1 in RCC tumours was associated with 
improved overall patient survival based on interrogation of the TCGA database. My pre-clinical 
orthotopic model suggests that KIM-1 may play a protective role in RCC. KIM-1 expression in 
RCC tumours positively correlated with transcripts for several collagen genes in human RCC 
patients. I observed significant discrepancies involving tumour progression and histological 
phenotypes between the subcutaneous and orthotopic murine RCC models. More research is 
required to fully discern the role of KIM-1 expression in RCC tumour progression, as KIM-1 








Appendix 1. Confirmation of KIM-1 expression (KIM-1pos) and absence of KIM-1 expression 
(KIM-1neg) through total cell protein lysate, mRNA expression, and cell surface expression of 









B.             C. 
                  
Supplementary Figure 1.  Renca RCC cell line protein, mRNA and surface level expression of 
KIM-1, respectively.  
Renca cells were transduced using a lentivirus carrying a vector encoding for murine KIM-1 
cDNA (KIM-1pos) or empty vector (KIM-1neg). A, Western blot to detect murine KIM-1 in KIM-
1pos and KIM-1neg Renca cells. B, Relative mRNA expression of KIM-1 (Havcr1) mRNA in 
KIM-1pos and KIM-1neg Renca cell lines normalized for expression of housekeeping gene 
GAPDH. C, KIM-1pos and KIM-1neg Renca cell line analysis of KIM-1 surface level expression 











Appendix 2. Periodate Lysine Paraformaldehyde Solution Protocol 
Materials for PLP Solution: 
• 0.1M Sodium Phosphate Buffer (Dibasic)  
● 14.18 g Na2HPO4 (Dibasic Sodium Phosphate) + 1L ddH2O 
• 0.1M Sodium Phosphate Buffer (Monobasic Sodium Phosphate)  
● 13.8g NaH2PO4 (Monobasic) + 1L ddH2O 
• 0.1M Phosphate Buffer (PB) – (stored RT) = 3:1 Dibasic buffer to Monobasic buffer 
• L-Lysine  
• Paraformaldehyde (PFA)  
• Sodium M-Periodate  
• Sucrose (10%, 20%, 30%) Dissolved in 0.1M Sodium Phosphate Buffer  
Freezing Tissue: 
● Dry Ice (store in Styrofoam box) 
● Ethanol (put within dry ice) 
● Isopentane (put in metal bin overtop of dry ice) 
● Optimal Cutting Temperature Compound (OCT)  
● Histology Tissue Cassettes 
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